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Peter J. Harrison, a Teresa M. Dunnb and Dominic J. Campopiano *aA new review covering up to 2018
Sphingolipids are essential molecules that, despite their long history, are still stimulating interest today. The
reasons for this are that, as well as playing structural roles within cell membranes, they have also been
shown to perform a myriad of cell signalling functions vital to the correct function of eukaryotic and
prokaryotic organisms. Indeed, sphingolipid disregulation that alters the tightly-controlled balance of these
key lipids has been closely linked to a number of diseases such as diabetes, asthma and various
neuropathologies. Sphingolipid biogenesis, metabolism and regulation is mediated by a large number of
enzymes, proteins and second messengers. There appears to be a core pathway common to all
sphingolipid-producing organisms but recent studies have begun to dissect out important, species-specific
differences. Many of these have only recently been discovered and in most cases the molecular and
biochemical details are only beginning to emerge. Where there is a direct link from classic biochemistry to
clinical symptoms, a number a drug companies have undertaken a medicinal chemistry campaign to try to
deliver a therapeutic intervention to alleviate a number of diseases. Where appropriate, we highlight targets
where natural products have been exploited as useful tools. Taking all these aspects into account this review
covers the structural, mechanistic and regulatory features of sphingolipid biosynthetic and metabolic enzymes.1 Introduction
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The chemistry and biology of sphingolipids (SLs) is a complicated
eld of research that requires an understanding of protein
chemistry, enzyme kinetics, cellular and structural biology, pro-
teomics, lipidomics and pathogenesis to fully appreciate the
fundamental roles that these molecules play across eukaryotic
and some prokaryotic species. Despite rst being identied over
130 years ago, the myriad roles of SLs in biology are only now
beginning to be understood.1 SLs are part of a larger lipid family2
and are essential structural components of cell membranes and
important signalling molecules that have been implicated in
a wide variety of different cellular processes such as cell differ-
entiation, pathogenesis and apoptosis.3–5 It is not surprising,
therefore, that we are still discovering new roles of SLs today.
All SLs are derived from L-serine and a fatty acid that together
dene a “sphingoid” base, also referred to as a long chain baseNat. Prod. Rep.
Fig. 1 (A) Chemical structures of the sphingoid base backbone, which
forms the core of all SLs. The L-serine derived moiety is highlighted in
green and the fatty acyl-CoAmoiety is highlighted in pink. The C1 and C2
hydroxyl and amines, the sites of further modification which generates
complex SLs, are also highlighted. (B) N-Acylation of the sphingoid base























































































View Article Online(LCB) (Fig. 1a). Diversity in SLs is generated through variations
in the fatty acid and the C1 head group and can be further
expanded by acylation of the C2 amine by fatty acids of varying
chain length. N-Acylation generates the ceramides (Fig. 1b,
showing C16 ceramide, which can be considered as the base unit
for SLs) and, for example, in plants, a combination of nine
different LCBs with thirty two different fatty acids gives rise to
a pool of 288 possible different ceramides.6 A vast, extensive
reservoir of SLs and ceramides is possible through attachment
of different head groups such as sugars, phosphate, fatty acid,
phosphoinositol or phosphocholine to the C1 hydroxyl.7 This
variation generates potentially well over 1000 structurally
distinct SLs. As a result of these variations, the SL prole of
organisms varies between taxa and indeed between species. For
example, plants and yeast produce a sphingoid base, phytos-
phingosine, which contains a C4 hydroxyl, which is notgenerates ceramide. Shown is atypical ceramide derived from palmitoyl-
CoA and N-acylation with C16-CoA (d18:1; c16:0). Further complexity is
added by addition of head groups to the C1 hydroxyl.Peter Harrison completed his
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Nat. Prod. Rep.abundant in mammals. Similarly the yeast Saccharomyces cer-
evisiae produces phosphoinositol containing complex SLs
whilst both phosphoinositol and glucosylceramide-containing
SLs are found in Pichia pastoris.8,9 This SL pool, known as the
“sphingolipidome”, is in constant dynamic ux and is subject to
the metabolic demands on the cell; a balance is struck between
de novo biosynthesis and breakdown/recycling. SL homeostasis
is maintained through complex regulatory pathways, the details
of which are only now being understood.10
The biosynthesis of SLs can be thought of as being split up
into three parts (Fig. 2, which gives a general overview of SL
biosynthesis). These three parts consist of the biosynthesis of
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Fig. 2 General overview of the SL biosynthesis pathway. There are, however, variations in the different types of sphingoid bases and ceramides
produced across different organisms. As such, this general overview omits details such as C4 hydroxylation to produce phytosphingosine in
plants, yeast and fungi.























































































View Article Onlineceramides (by the attachment of an amide linked fatty acid) and
nally, formationation of complex SLs (through the attachment
of head groups to C1 of the sphingoid base). SL biosynthesis
and metabolism is intriguing in that, in all organisms studied
to date, the pathway is bookended by two pyridoxal 50-phos-
phate (PLP) dependent enzymes (Fig. 2); serine palmitoyl-
transferase (SPT) and sphingosine 1-phosphate lyase (S1PL).
The de novo pathway begins with SPT, which catalyses the
decarboxylative, Claisen-like condensation of L-serine with pal-
mitoyl coenzyme-A (palmitoyl-CoA) to form 3-ketosphinganineThis journal is © The Royal Society of Chemistry 2018(3-keto-dihydrosphingosine, 3-KDS). This SPT-catalysed reac-
tion denes the 2S,3R (D-erythro diastereomer) stereochemistry
of all downstream SLs and ceramides. The breakdown of SLs
requires an LCB phosphate lyase (LCB1PL more commonly
known as called S1PL), which performs a retro-aldol like
cleavage of LCB 1-phosphate to phosphoethanolamine (PEA)
and a long chain aldehyde (e.g. 2E-hexadecanal (2E-HEX)).11,12 In
eukaryotes the majority of SL biosynthesis begins in the endo-
plasmic reticulum (ER).7,13 Thereaer, complex SL biosynthesis
primarily occurs in the Golgi apparatus (although some SLs, forNat. Prod. Rep.
Table 1 UniProt and PDB codes for characterised enzymes discussed in this review (references refer to the PDB entries)
Enzyme Organism UniProt code(s) PDB code(s) Ref.
SPT Sphingomonas paucimobilis Q93UV0 2JG2, 2JGT, 2W8J, 2W8T, 2W8U,
2W8V, 2W8W, 2XBN
39, 59 and 153
SPT Sphingomonas multivorum A7BFV6 3A2B 58
SPT Sphingomonas spiritivorum A7BFV7 —
SPT Sphingomonas wittichii A5VD79 2X8U 54
SPT Bdellovibrio stolpii A7BFV8 —
SPT Bacteroides fragilis Q5LCK4 —
SPT Porphyromonas gingivalis Q7MTZ6 —
SPT Saccharomyces cerevisiae P25045 (LCB1), P40970 (LCB2) —
SPT Homo sapiens O15269 (HsSPT1), O15270 (HsSPT2),
Q9NUV7 (HsSPT3)
—
SPT Toxoplasma gondii B9PTE5 (TgSPT1), B9QEB0 (TgSPT2) —
SPT Mus musculus O35704 (SPT1), P97363 (SPT2) —
ssSPT Saccharomyces cerevisiae Q3E790 (Tsc3p) —
ssSPT Homo sapiens Q969W0 (ssSPTa), Q8NFR3 (ssSPTb) —
ORMDL Homo sapiens Q9P0S3 (ORMDL1), Q53FV1 (ORMDL2),
Q8N138 (ORMDL3)
—
ORM Saccharomyces cerevisiae P53224 (ORM1), Q06144 (ORM2) —
KDSR Saccharomyces cerevisiae P38342 —
KDSR Candida albicans Q59RQ2 —
KDSR Aspergillus fumigatus Q4WSZ0 —
KDSR Homo sapiens Q06136 —
SK Homo sapiens Q9NYA1 (SK1), Q9NRA0 (SK2) 3VZC, 3VZD, 3VZB, 4L02, 4V24 237, 249 and 250
SK Saccharomyces cerevisiae Q12246 (LCB4), Q06147 (LCB5) —
S1PL Saccharomyces cerevisiae Q05567 (Dp11p) 3MC6, 271
S1PL Homo sapiens O95470 4Q6R 284
S1PL Burkholderia pseudomallei Q63IP8 (S1PL2021), Q63IP4 (S1PL2025) 5K1R 278
S1PL Symbiobacterium thermophilum Q67PY4 3MBB, 3MAU, 3MAF, 3MAD,
5EUE, 5EUD
271 and 285
S1PL Legionella pneumophila Q5ZTI6 4W8I 276























































































View Article Onlineexample sphingomyelin, can also be made in the plasma
membrane).14,15 In addition to the de novo synthesis of SLs
detailed above, SLs can also be formed from the turnover and
recycling of LCBs and ceramides, which can then be fed back
into the SL pool.11,12
SL levels are tightly controlled in cells. However, the molec-
ular details by which SL levels are regulated are not currently
understood in great detail. Disruption of SL homeostasis can
give rise to disease states.16,17 Mutations to enzymes in the SL
biosynthesis pathway also give rise to disease. For example,
hereditary sensory and autonomic neuropathy type 1 (HSAN1)
results from the formation of deoxysphingolipids (deoxy-SLs)
which cannot be removed from the SL pool by the LCB1P
lyase dependent pathway.17,18 The formation of these deoxy-SLs
and their potential role as biomarkers for disease makes them
of pharmaceutical interest.
The biological role of SLs and the complex interplay of sig-
nalling pathways that occurs in SL signalling is beyond the
scope of this review. However, understanding the roles of SLs
and the SL rheostat is a rapidly developing area of research.
Several excellent recent review articles provide more informa-
tion on the structure and function of SLs and the regulation of
SLs.6,8,9 Readers are particularly directed to Alfred Merrill's 2011
seminal review of SLs which provides an excellent overview of SL
structure and function.7,19 Here we will focus on the enzymes of
SL biosynthesis and breakdown which have been structurallyNat. Prod. Rep.characterised and have been the target of medicinal chemistry
campaigns by various pharmaceutical companies. A complete
list of the enzymes discussed in this review, along with their
associated UniProt and PDB codes is provided in Table 1. We
also want to emphasise that SLs are also found in some
prokaryotes and other higher organisms and we will discuss
examples from across the phylogenetic tree of life.2 Serine palmitoyltransferase (SPT)
The rst step in de novo SL biosynthesis is the condensation of L-
serine with palmitoyl-CoA, catalysed by serine palmitoyltransfer-
ase (SPT), to form 3-KDS, the sphingoid base which is the starting
point for all SLs (Fig. 2).20–22 The role of SPT as the rst enzyme is
conserved across all organisms studied to date. However, there are
important differences in SPT biochemistry between taxa, one of
the most signicant being the subcellular localisation of the
enzyme – in bacteria the enzyme is cytoplasmic, whereas in yeast,
plants and mammals the enzyme is localised to the ER.232.1 Enzymology of SPT
SPT is a PLP-dependent enzyme, one of the broadest super-
families of enzymes. PLP enzymes catalyse a wide variety of
chemical reactions including C–C bond formation (8-amino-7-
oxononanoate synthase (AONS)),24 C–C bond cleavage (serineThis journal is © The Royal Society of Chemistry 2018
Fig. 3 Proposed catalytic mechanism for SPT based on studies per-
formed on Sphingomonas SPT and by analogy to other AOS family
members. Briefly, binding of L-serine displaces PLP bound as an
internal aldimine (Schiff's base) to the conserved active site lysine to
form a PLP:L-serine external aldimine. Acyl-CoA binding causes
abstraction of the a-proton from L-serine. Electron rebound onto the
acyl-CoA thioester forms the C–C bond and releases free CoASH.
Subsequent decarboxylation and displacement by the lysine side chain
releases the 3-KDS product and re-forms the internal aldimine.























































































View Article Onlinehydroxymethyltransferase),25 racemisation (alanine race-
mase),26 transamination (aspartate aminotransferase),27 decar-
boxylation (3,4-dihydroxyphynlalanine decarboxylase)28 and
dehydration (threonine dehydratase).29 Their substrates tend to
be amino acids but they also play important roles in essential
pathways such as cell wall30 and vitamin biosynthesis,24 anti-
biotic resistance31 and neurotransmitter metabolism.28 PLP
enzymes display similarities in amino acid sequence, 3D
structural fold and enzyme mechanism. SPT catalyses the
formation of 3-KDS, an a-oxoamine and thus is part of the a-
oxoamine synthase (AOS) family that catalyses Claisen like
condensation reactions between amino acid and acyl-CoA
substrates. The PLP superfamily has been sub-classied
according to 3D structure, and sequence analysis places all
SPTs characterised to date in the type-1 subfamily of PLP-
dependent enzymes32–34 The catalytic mechanism of type-1
PLP enzymes is heavily inuenced by the way the enzyme
binds the PLP cofactor and its substrates within the catalytic
fold. The best characterised AOS members are 5-amino-
levulinate synthase (ALAS, heme biosynthesis),35 AONS (biotin
biosynthesis),24 2-amino-3-ketobutyrate coenzyme A ligase
(KBL, L-threonine degradation)36 and CqsA (quorum sensing
molecule biosynthesis).37 Although the extent to which the
mechanism is conserved across AOS superfamily members is
unknown, by using mechanistic data from across the family
a catalytic mechanism for SPT was proposed.38 Evidence for
these proposals has been obtained by the recent structural and
mechanistic studies on the soluble, cytoplasmic bacterial SPTs
from Sphingomonas paucimobilis and Sphingomonas
multivorum.39–43
In the resting state of the prokaryotic SPT enzyme the PLP
cofactor is bound to the enzyme at an active site lysine through
a Schiff base linkage (Fig. 3). This can be observed spectro-
photometrically through two characteristic absorbance maxima
at 333 nm and 420 nm (corresponding to the enolimine and
ketoenamine tautomers of PLP-Lys respectively) and is referred
to as the internal aldimine.44,45 The SPT reaction begins with the
binding of L-serine to the active site, which displaces lysine from
PLP to form the PLP:L-Ser external aldimine complex. This is
characterised by a decrease in absorbance at 333 nm with
a concurrent increase at 425 nm (with the absorbance maxima
shiing slightly from 420 nm in the internal aldimine).
Following formation of the external aldimine, the second
substrate (the palmitoyl-CoA thioester) binds, which is thought
to cause a conformational change. This brings the proposed
base – the PLP-binding lysine – in close enough proximity to
allow proton abstraction from Ca and the formation of
a quinonoid/carbanion intermediate. Electron rebound from
the PLP cofactor then allows for nucleophilic attack on the
palmitoyl-CoA thioester and stereoselective C–C bond forma-
tion. Following this, decarboxylation occurs readily from the b-
keto acid intermediate, forming the PLP:3-KDS external aldi-
mine product by abstracting an active site proton. Experiments
with [2,3,3-2H3]-L-serine have shown that the a proton of serine
is not retained in the 3-KDS product, implying that either the
active site proton used to form the product 3-KDS is derived
from bulk water, or that the initially abstracted proton is rapidlyThis journal is © The Royal Society of Chemistry 2018exchanged with bulk water.46 The 3-KDS is subsequently dis-
placed from the PLP:3-KDS complex by the active site lysine,
releasing the 3-KDS and allowing another round of catalysis to
begin.
For some time, there was debate as to the true course of the
SPT reaction. Did decarboxylation occur rst, forming a quino-
noid which then condensed onto the palmitoyl-CoA, or did a-
proton deprotonation occur rst? Experiments on a-oxamine
family members (AONS, ALAS and SPT) whereby the a-proton is
not retained in the nal product indicate that the a-proton
abstraction is the rst step.46–48 Additional experiments on ALAS
and AONS also lend support to the deprotonation-rst mecha-
nism.49,50 More direct proof for deprotonation as the rst stepNat. Prod. Rep.























































































View Article Onlinewas provided by an elegant set of experiments performed by
Ikushiro and colleagues.43 A modied palmitoyl-CoA substrate
analogue was synthesised, in which a methylene bridge was
inserted between the sulphur atom and the carbonyl, to form an
acyl-thioether (S-(2-oxoheptadecyl)-CoA). This subtle modica-
tion allows the analogue to bind to the SPT PLP:L-serine external
aldmine complex and for the presumed conformational change
to occur that would allow deprotonation from Ca. However, the
thioether prevents cleavage of the acyl moiety from CoA, thus
trapping the PLP enzyme complex in a substrate-activated state.
Ikushiro then used 1H NMR to monitor proton signals of L-
serine during the course of the reaction. The addition of L-serine
to SPT (formation of the external aldimine) did not alter the
chemical shi of the L-serine protons. However, the subsequent
addition of the acyl-thioether analogue caused a change in the
chemical shis consistent with a-deprotonation (forming the
quinonoid intermediate) at 100-fold increased rate. This
quinonoid intermediate was observed spectrophotometrically
by the formation of a peak at 490 nm, which is stable for several
hours at room temperature. Consequently, palmitoyl-CoA
binding is a prerequisite for a-deprotonation and subsequent
attack onto the thio-ether of palmitoyl-CoA.40Fig. 4 Structures of unusual bacterial sphingolipids. Bdellovibrio
stolpii sphingophosphonolipid (stereochemistry not reported), RIF-1
from Algoriphagus machipongonensis and Bacteroides fragilis iso-
branched galactosylceramide.2.2 SPT in bacteria
SLs are not commonly found as components of either Gram
positive or negative bacterial membranes. However, SLs have
been identied in a select group of microbes, including the
Bacteroides and Sphingomonads.51,52 The purication of a bacte-
rial SPT from crude cell lysate was rst reported by Lev &Milford
in 1981, who puried an enzyme with what they referred to as
“3-ketodihydrosphingosine synthetase” activity from Bacter-
oides melaninogenicus >100 fold from cell free extracts.53 This B.
melaninogenicus SPT demonstrated a preference for palmitoyl-
CoA, but could utilise a variety of different acyl-CoA
substrates, from as short as decanoyl-CoA (C10) to as long as
oleoyl-CoA (C18).
The rst purication of a bacterial SPT to homogeneity was
reported by Ikushiro et al. in 2001 from S. paucimobilis, which
also allowed the encoding gene to be cloned and sequenced
(SpSPT, Q93UV0, Table 1).44 The SpSPT displays 30% homology
with other AONS family members and contains the conserved
PLP binding lysine residue (Lys265). Recombinant SpSPT iso-
lated from E. coli is a soluble homodimer and binds one
molecule of PLP per subunit, and also exhibits a tolerance to
a range of acyl-CoA substrates, similar to B. melaninogenicus
SPT. Interestingly, when expressed heterologously in E. coli, the
host produces the 3-KDS product from endogenous L-serine and
palmitoyl-CoA (Gable et al., unpublished).
SPT has been identied in other Sphingomonas bacterial
strains including S. multivorum (A7BFV6), S. spiritivorum
(A7BFV7) S. wittichii (A5VD79) and Bdellovibrio stolpii (Bacter-
iovorax stolpii, A7BFV8) with each enzyme displaying high
sequence homology and biochemical properties similar to the
S. paucimobilis SPT.42,54 B. stolpii is an interesting case in that it
contains a unique SL head group with an unusual phosphonate
linkage to the C1 of the sphingoid base, which appears to beNat. Prod. Rep.important in the lifecycle of the organism (Fig. 4).55,56 There is
some evidence that, in vivo, the SPTs from S. multivorum and B.
stolpii SPT cluster around the inner cell membrane suggesting
that these SPT enzymes may release the highly hydrophobic
KDS product directly into the membrane. Interestingly, in the S.
wittichii genome, the SPT is located adjacent to an acyl-carrier
protein (ACP).54 This has led to the hypothesis that S. wittichii
SPT is able to accept C16 units from an ACP thioester rather than
an acyl-CoA.
A crystal structure of S. multivorum SPT with bound PLP was
rst reported in 2006.57 However, the rst published SPT
structure with an associated Protein Databank (PDB) le
detailing the X-ray coordinates (S. paucimobilis SPT, SpSPT) was
determined by Yard et al. and reported in 2007 39 (Fig. 5). This
structure was then followed by reports of the S. multivorum
SPT58 (PDB: 3A2B) and S. witichii SPT (PDB: 2X8U).54 For clarity,
here we will use the S. paucimobilis SPT sequence when referring
to amino acid residues. Analysis of the structures of S. pauci-
mobilis SPT reveals that SPT is a homodimeric complex, with an
overall topology which resembles other type-1 PLP family
enzymes such as AONS, KBL and ALAS.39 Each SPT monomer
consists of three domains; N-terminal, central catalytic and C-
terminal, all three of which are involved in the dimerization
of SPT. The N-terminal domain is short, comprising only 80
amino acids which form an a-helix and an antiparallel b-sheet.
The central catalytic domain is dominated by a seven stranded
b-sheet structure, which is characteristic of type-1 PLP enzymes.
The catalytic lysine, Lys265, is located in this domain. Finally,
the mostly a-helical, C-terminal region consists of approxi-
mately 100 residues. The SPT active site is formed at the dimer
interface and contains the active site lysine to which the PLP
attaches as the internal aldimine.39 Residues from bothThis journal is © The Royal Society of Chemistry 2018
Fig. 5 The 3D structures of S. paucimobilis SPT in the internal aldimine (top, PDB: 2JG2) and external aldimine (bottom, PDB: 2W8J) forms. The
active sites are shown, highlighting key residues. To highlight the dimeric nature of SPT, one of the SPTmonomers is shown in ribbon form, whilst
the other is shown as a surface representation. An overlay of the active sites in the internal and external aldimine forms is shown in Fig. 6.























































































View Article Onlinesubunits form the active site, and since bacterial SPT is
a homodimeric complex there is a 1 : 1 stoichiometry between
the number of subunits and the number of active sites (i.e. two
active sites per dimer). The two long hydrophobic channels that
lead from the active site to the surface of the enzyme have been
proposed to act as binding pockets for the hydrophobic
palmitoyl-CoA substrate.39,58 However, no electron density cor-
responding to palmitoyl-CoA has been found in crystals of SPT,
therefore which channel is required for palmitoyl-CoA binding
is unknown.
The determination of the X-ray structure of the SpSPT PLP:L-
serine complex by Raman et al. (PDB: 2W8J), allowed
a comparison of the internal (PLP-bound) and external (PLP:L-
serine) aldimine forms of the enzyme.59 There is an extensive
hydrogen bonding network between the PLP cofactor and resi-
dues of the active site. Of particular note is His234, which
hydrogen bonds with the PLP hydroxyl and Asp231 which
hydrogen bonds with the protonated pyridine nitrogen
(protonation of the pyridine nitrogen is required for a-proton
abstraction in PLP enzymes).60 The phosphate of PLP forms the
centre of a phosphate binding cup, hydrogen bonding with
residues of both subunits.39,41 These interactions are all retained
in the external aldimine form of the enzyme.58,59
Formation of the SPT:PLP–L-serine external aldimine
complex is accompanied by several structural changes (Fig. 6).
His159 sits on one face of the PLP-pyridine ring, forming a p–p
stacking interaction and is required for PLP binding to theThis journal is © The Royal Society of Chemistry 2018enzyme. This histidine residue is the rst of three consecutive
residues (His–Ala–Ser) which are strictly conserved amongst
AOS family members. Mutational analysis suggests that His159
plays multiple roles in SPT with involvement in substrate
recognition and catalysis.61 It is proposed that His159 aids in
recognition of L-serine by forming a hydrogen bond with the
carboxylate of the L-serine. This is important as it ensures that
the Ca-COO bond is almost perpendicular to the plane of the
pyridoxal nitrogen of the PLP–L-serine-external aldimine.62 As
suggested by Dunathan, it is the bond perpendicular to the
plane of the pyridoxal nitrogen which is preferentially cleaved.63
By xing the conformation of the external aldimine, deproto-
nation is prevented until binding of the second substrate,
palmitoyl-CoA, thus preventing the enzyme from undergoing an
abortive transamination reaction. Binding of palmitoyl-CoA is
proposed to disrupt the hydrogen bond of His159 with the L-
serine carboxylate, which results in rotation of L-serine, allowing
the carboxylate to form an interaction with Arg390. These
structural changes position the Ca–H bond of L-serine perpen-
dicular to the plane of the pyridine nitrogen, allowing depro-
tonation to occur and the reaction to proceed. The role of
Arg390 in catalysis aer the formation of the external aldimine
is supported by mutational experiments.40 In S. witichii, when
the arginine analogous to Arg390 (Arg370) is mutated, forma-
tion of the external aldimine is not perturbed.54 However, when
S-(2-oxoheptadecyl)-CoA is added to the reaction, no substrate
quinonoid is formed (that can be detected).Nat. Prod. Rep.
Fig. 6 Overlay of the internal (green carbon atoms) and external
(purple carbon atoms) of S. paucimobilis SPT. Hydrogen bonds of L-
serine to His159 and Arg378 are also shown. The large movement of
Arg378 from the internal to external aldimine forms is evident.























































































View Article OnlineOther changes also occur on the formation of the external
aldimine. Of note is the positioning of Lys265, which moves
approximately 4 Å. This results in a hydrogen bond between
Lys265 and the hydroxyl group of L-serine.58,59 The hydroxyl of L-
serine hydrogen bonds with the PLP phosphate, contributing to
the phosphate binding cup.41 This interaction has been shown
to be required for optimal activity of the SPT enzyme. Addi-
tionally, in the external aldimine form, Arg378 swings into the
active site, forming a salt-bridge with the carboxylate of the L-
serine on the external aldimine.58,59 The effect of these changes
in the structure on the formation of the external aldimine is to
ensure, as discussed above, that the Ca–H bond is not
perpendicular to the pyridoxal nitrogen.
A variety of different SL-like natural products have been
identied in bacteria. The marine bacterium Algoriphagus
machipongonensis co-habits in the same environment with the
marine organism Salpingoeca rosetta and produces a signalling
compound known as Rosette Inducing Factor (RIF, Fig. 4).64
Although chemically similar to an SL, RIF is in fact a sulfonoli-
pid which is required to trigger multicellular rosette colony
formation in S. rosetta. Similarly, SL-like natural product
inhibitors of SPT have been identied in bacteria and fungi (see
Section 2.8). Although the precise biosynthetic pathways of
these compounds is unknown, retro-biosynthetic analysis
suggests that an SPT-like reaction could be involved. If true, this
demonstrates the central role that SPT-like enzymes and other
AOSs play in the biosynthesis of many different compounds.
Additional interest in bacterial SPTs has been generated
through the investigation of the roles that SLs play in Bacter-
oides, the most abundant genus of human gut commensal
bacteria.65 Of particular interest is Bacteroides fragilis, an
opportunistic pathogen which has been linked to inammatoryNat. Prod. Rep.bowel disease and colon cancer and whose membrane consists
of 40–70% SLs.66,67 B. fragilis has been suggested to modulate
the host immune system through a-galactosylceramides, which
are proposed to be produced from iso-branched sphingoid
bases (Fig. 4).68,69 Consequentially, an SPT-like enzyme probably
catalyses a key step in the biosynthesis of these molecules. A
putative SPT with high homology (32.5% identity) to SpSPT has
recently been identied in the oral dental pathogen Porphyr-
omonas gingivalis (a Bacteroides),70 a bacteria known to produce
sphingolipids.71–73 Deletion of the gene (PG1780) encoding this
enzyme from strain W83 abolished SL production, diminished
the long-term survival of P. gingivalis and impacted the cell
surface properties of the PG1780 mutant strain. A detailed
understanding of the biosynthesis of SLs in the human micro-
biome (both commensals and pathogens) will shed light on
their roles in mediating host–bacteria interactions, as well as
potentially aiding in the development of novel antimicrobial
therapeutics. The role of sphingolipids in host–microbial
interactions has recently been eloquently reviewed,74 and
sphingolipids have been identied in other oral microbiome
bacterium by Nichols.752.3 SPT in viruses
Large scale genomic sequencing has allowed the identica-
tion of SPT genes in different organisms from interesting and
unexpected biological niches. Genes encoding SPT and other
proteins involved in SL metabolism have been found in the
marine virus Coccolithovirus, a pathogen which infects the
plankton Emiliania huxleyi.76 In a seminal study, it was shown
that viral SLs induce lysis and cell death which leads to the
breakdown of algal blooms.77–79 These viral-derived glyco-
sphingolipids can cause programmed cell death in an unin-
fected E. huxleyi host and were detected in high enough
concentrations in the coccolithophore populations in the
North Atlantic Ocean to be deemed effective biomarkers for
viral infection. Interestingly, the SPT gene in Coccolithovirus is
a natural chimera of two subunits, analogous to the eukary-
otic SPT subunits (SPT1 and SPT2, see Section 2.5 below), and
is expressed as a single polypeptide chain.76,80 The N-terminal
domain of the protein is predicted to contain the essential,
conserved lysine residue required for binding of the PLP
cofactor (making it analogous to SPT2), whilst the C-terminal
domain is, by sequence alignment, analogous to SPT1.80 The
Coccolithoviral SPT chimera was able to complement growth
in yeast lacking endogenous SPT, although the activity of
Coccolithoviral SPT was signicantly lower than the SPT from
yeast. Signicantly, in vitro assays using microsomes con-
taining the Coccolithoviral SPT revealed a preference for C14-
CoA (myristoyl-CoA) as a substrate over C16-CoA (palmitoyl-
CoA). Infection of E. huxleyi with Coccolithovirus also alters
the LCB prole of the host, ‘rewiring’ ceramide synthesis in E.
huxleyi.81 A recent biochemical study of the Coccolithovirus
and E. huxleyi pathways suggests that the viral SPT encodes
the key switch that diverts metabolism towards the formation
of the toxic SL which ultimately leads to the death of the
phytoplankton.81This journal is © The Royal Society of Chemistry 2018























































































View Article Online2.4 SPT in yeast and fungi
Over many years the yeast S. cerevisiae has played a pivotal role
in dening the genes, pathways and enzymology of SL biosyn-
thesis in a higher eukaryote. In yeast and other higher order
species, SL biosynthesis occurs in the ER. SPT was identied in
yeast through genetic screens, one designed to nd auxotrophs
that required LCBs for growth82–86 and another that identied
suppressors of the csg2D mutant, defective in complex sphin-
golipid biosynthesis.87 It was found that two genes, lcb1 (long
chain base) and lcb2 were required for SPT activity. Both enco-
ded gene products, LCB1 and LCB2, belonging to the AOS
family of enzymes, and deletion of either lcb1 or lcb2 was found
to abolish SL biosynthesis in yeast.85,87 For the sake of
simplicity, we will refer to LCB1 as SPT1 and LCB2 as SPT2.
Sequence alignment of SPT1 and SPT2 with other members of
the AOS family shows that whilst SPT2 contains the conserved
lysine required for PLP binding, SPT1 does not (Fig. 7).82,88,89 In
view of this observation, an early hypothesis was that SPT2 was
a “catalytic” subunit and SPT1 performed some regulatory role
in the SPT-catalysed reaction. Modelling studies with AONS led
to the suggestion that the SPT active site lay at the interface
between the two subunits of an SPT1/SPT2 heterodimer.90
Subsequently, determination of the bacterial SpSPT structure
and mechanism highlighted a number of residues required for
L-serine and acyl-CoA substrate binding and catalysis; namely
His159, His234, Asp231, Arg390 (numbering in SpSPT). Resi-
dues analogues to these amino acids are lacking in SPT1.39,40,61
Immunoprecipitation experiments demonstrated that SPT1
and SPT2 form a heterodimeric complex, presumably contain-
ing a single active site, with the PLP binding lysine provided by
SPT2.82,90 This heterodimeric arrangement is unique amongst
AOS family members since others are homodimers. However,
this raises questions as to the role of SPT1, and whether it has
a regulatory function (see Section 2.7). Further experiments
indicated that SPT2 is unstable in the absence of SPT1, sug-
gesting a more intimate dimeric partnership.91 However, the
PLP binding capacity of either SPT1 or SPT2 has yet to be
demonstrated in vitro. Topological experiments revealed that
SPT1 consists of three transmembrane helices with the N-
terminal domain located in the ER lumen and the C-terminal
domain located in the cytosol.92 Moreover, the central and C-
terminal domains of the enzyme were shown to be requiredFig. 7 Partial sequence alignment of serine palmitoyltransferases with o
conserved lysine residue which is not present in the SPT1 subunits of SP
This journal is © The Royal Society of Chemistry 2018for the stability of the SPT2 subunit through site directed
mutagenesis and deletion experiments. These data, taken
together, suggest that SPT1 and SPT2 interact in both the
membrane and in the cytosol and that in the absence of SPT1,
SPT2 is not stable.
An important third SPT subunit was identied by Dunn and
co-workers, termed Tsc3p.91 Tsc3p was shown to be a novel 80
amino acid membrane-associated protein which co-
immunoprecipitates with SPT1 and SPT2, but is not essential
for SPT activity. However, microsomal preparations from
a tsc3D S. cerevisiae mutant were shown to have 30-fold lower
SPT activity than those from the wild type strain, showing that
Tsc3p is required for optimal, high level SPT activity during
maximal SL biosynthesis. The exact molecular details of how
Tsc3p exerts its stimulating activity on the SPT complex is
unknown.
2.5 SPT in mammals
Once the genes that encode SPT in yeast had been discovered it
was not long before the homologues of yeast SPT1 and SPT2
were identied in humans (SPT1: O15269 and SPT2: O15270),
mice (SPT1: O35704 and SPT2: P97363) and other mammals via
sequence analysis and functional complementation assays.93–95
Between human and yeast SPT1 there is 30.9% identity and
46.3% similarity whilst between human and yeast SPT2 there is
42.2% identity and 60.7% similarity, suggesting that the roles of
SPT1 and SPT2 in mammals and yeast are analogous.95 As with
the yeast SPT1 and SPT2 isoforms, experiments with the
mammalian SPT1 and SPT2 indicted that both were absolutely
required for catalytic activity, and mutation of the putative PLP
cofactor binding lysine residue in SPT2 abolished catalytic
activity even in the presence of SPT1, which lacks the PLP
binding motif.93 Additionally, levels of mRNA transcripts for the
SPT1 and SPT2 subunits of SPT correlate in their tissue distri-
bution, as is to be expected for subunits of the same complex.95
Detailed biochemical characterisation of the SPT complex
was not achieved until 2000 when the SPT complex from
hamster was puried by Hanada and co-workers via the use of
affinity peptide chromatography.96 They took advantage of a LY-
B strain, which is a CHO cell line defective in SPT activity due to
a G246Rmutation in the SPT1 protein.97 Puried SPT was found
to show a strong preference for L-serine. The acyl-CoA specicityther AOS family members (ALAS, CqsA, KBL and BioF), highlighting the
T heterodimers.
Nat. Prod. Rep.























































































View Article Onlineof the SPT complex was also found to be quite narrow. Although
palmitoyl-CoA (C16) was the preferred substrate, other acyl-CoA
substrates, such as pentadecanoyl- (C15) and heptadecanoyl-CoA
(C17) were also accepted. Shorter (myristoyl-CoA, C14), longer
(stearoyl-CoA, C18) and modied acyl-CoA substrates (arach-
idonoyl- and palmitoleoyl-CoA) were not turned over. Using
a combined western blot/radiolabelling/immunoprecipitation
approach, the stoichiometry of SPT1 and SPT2 in the mamma-
lian complex was determined to be 1 : 1, suggesting a hetero-
dimeric complex, although a heterotetrameric complex is also
possible.96 Interestingly, the nature of the SPT1 defect in the
useful LY-B CHO cell line was not resolved until 2009 by Merrill,
Hanada and colleagues. By sequencing the SPT1 transcript from
LY-B cells they found a single mutation (G246R) which caused the
translated protein to be unstable and thus barely detectable in
protein and SPT assays. They also attempted to model why such
a mutation would be so deleterious to the SPT1 protein and
predicted this residue could not be accommodated in a conserved
hydrophobic pocket.97
Topological studies onmammalian SPT1 give results that are
consistent with those obtained on yeast SPT1 (Fig. 8).92,98
Mammalian SPT1 is localised to the ER with the N-terminus of
the protein in the ER lumen and the C-terminus exposed to the
cytosol. Similar to its yeast homologue, human SPT1 was also
found to be necessary for the stability of SPT2. The positioning
of the termini of SPT1 indicates that SPT1 must have an odd
number of transmembrane helices. Yasuda et al. suggest that
human SPT1 contains a single transmembrane spanning
domain, since other domains in SPT1 have similarity to soluble
AOS family members and that other hydrophobic regions form
the internal region of a large soluble globular domain. Subse-
quent work by Han et al. on yeast SPT1 cast doubt on this initial
topology model. By inserting the glycosylation cassette from the
invertase Suc2p at various sites into SPT1 and monitoring
whether the resultant protein was glycosylated or not, Han and
co-workers obtained results which led them to propose that
SPT1 has three transmembrane domains. This model is further
supported by protease accessibility studies. These topological
studies remain the only structural insight into the human SPTFig. 8 Proposed transmembrane domain topologies of human SPT1
and SPT2 within the ER membrane. The active site lysine required for
PLP binding is located on SPT2.
Nat. Prod. Rep.complex since there is, as yet, no high resolution data for
mammalian SPT1 or SPT2.92
Detailed understanding of the human SPT complex has been
further complicated by the identication of a second homo-
logue of yeast SPT2 in humans, termed SPT3 (SPTLC3), or
SPT2b (Q9NUV7). SPT3 shows 68% homology to SPT2, has
similar enzymatic functions and is proposed to form a dimer
with SPT1 in a fashion similar to SPT2.99 However, the tissue
expression pattern of SPT2 and SPT3 vary, with the highest
expression of SPT3 in both placenta and human trophoblast
suggesting that it may alter either the activity of the SPT
complex or the substrate specicity of the complex.99 This
turned out to be correct when it was found that the acyl-CoA
chain selectivity of a SPT complex containing SPT3 displayed
a preference for C14-CoAs and thus generated C16-derived SLs in
the tissues expressing this subunit.100
Additionally, motivated by their discovery of Tsc3p and the
observation that co-overexpression of SPT1 and SPT2 did not
cause a corresponding increase in SPT activity in mammalian
cells, Dunn and colleagues identied small subunits of human
SPT, functionally analogous to Tsc3p in yeast, termed ssSPTa
(small subunit) and ssSPTb.101 These human SPT subunits are
small (9 kDa), hydrophobic proteins that display 57% sequence
similarity and 36.7% identity to each other. However, neither
ssSPTa nor ssSPTb displays signicant sequence homology to
Tsc3p. As such, ssSPTa/b were identied using an spt1Dspt2D S.
cerevisiae double knockout strain (TDY8055) in which expres-
sion of the human SPT1/2 without a small subunit supports
growth at 26 C. Growth is permitted at 37 C only by the
addition of the yeast-specic SL phytosphingosine. In order to
identify the human small subunits, a human cDNA library was
transformed into the yeast strain expressing human SPT1 and
SPT2 and transformants able to grow at 37 C were recovered.
Two functional orthologues of Tsc3p were identied, ssSPTa
and ssSPTb. The ssSPTb gene had been previously identied in
a screen for genes that were down regulated by androgen in
mouse prostate, but no function had been assigned, and since
the small subunits were found to co-purify with SPT and SPT2a/
b they were assigned as bone-de SPT subunits. Moreover, when
ssSPTa was co-expressed with SPT1 and SPT2 in microsomal
preparations of LY-B CHO cells, SPT activity was increased over
100 fold. Most interestingly, the resultant four different possible
isoforms of the SPT complex (SPT1–SPT2a–ssSPTa, SPT1–
SPT2a–ssSPTb, SPT1–SPT2b–ssSPTa, SPT1–SPT2b–ssSPTb) have
distinct acyl-CoA specicities. The SPT1–SPT2a–ssSPTa isoform
conferred a strong preference for C16-CoA, whilst the SPT1–
SPT2b–ssSPTa isoform was equally accepting of C14-CoA as C16-
CoA. In contrast to SPTs containing the ssSPTa isoforms, those
with the ssSPTb subunit display a preference for longer acyl-CoA
substrates, up to C20-CoA. For all four isoforms, the KM for L-
serine (1–2 mM) was the same with the preferred acyl-CoA
substrate. The acyl-CoA preference of SPT complex can also be
directly inuenced by mutation of a single residue in the small
subunits, demonstrating that the small subunits are crucial for
controlling the acyl-CoA preference of SPT.102,103 A more recent
study has identied a H65K mutation in ssSPTb in mice,
referred to as the Stellarmutation.102 The effect of this mutationThis journal is © The Royal Society of Chemistry 2018























































































View Article Onlineis to increase the proportion of C20 containing long chain bases
in tissues, in particular the eyes and brain, leading to a “eye
ecking” phenotype in young mice. Neuronal damage is also
observed, including early onset ataxia and death at 10 weeks in
homozygous mice carrying this single mutation. In microsomal
assays, SPT activity was unaffected with a C16-CoA substrate but
doubled with C18-CoA. The exact molecular details of how
elevated SLs in the Stellar mice lead to neuropathy and
increased mortality are unclear.
Deletion experiments have shown that with the small
subunit SPTs, neither the N- nor C-terminal domains are
essential.103 It is only the core 33 amino acids of ssSPTa which
are required for activation of the SPT heterodimer and for
conferring the acyl-CoA specicity of the complex. Of interest,
a single residue, Met25 in ssSPTa and Val25 in ssSPTb dictates
the acyl-CoA specicity. Surprisingly, a single M25Gmutation in
ssSPTa results in an alteration of the acyl-CoA specicity
towards longer (ssSPTb-specic C20) acyl-CoA substrates sug-
gesting this residue confers substrate specicity. Topological
analysis demonstrate that the N-termini of both ssSPTs is
cytoplasmic and suggest that the ssSPTs have a single trans-
membrane spanning domain, which comprises the core 33
amino acid region.101,103 However, at the molecular level, it is
unknown how the small subunit is able to confer these changes
in substrate specicity and how it interacts with the larger SPT
complex. The N-terminal domain of SPT1 can be deleted and
the resulting truncated form still displays enhanced SPT activity
in the presence of SPT2 and either of the small subunits,92
indicating this part of SPT1 does not interact with its small
activating partners. That said, it is also worth noting that
deletion of the N-terminal transmembrane domain of SPT1
does not prevent membrane association or SPT activity, clearly
supporting the presence of additional membrane spanning
domains.
The observation of acyl-CoA substrate promiscuity in the
eukaryotic SPT isoforms suggests that diversication in the
types of SLs produced begins very early in the SL biosynthesis
pathway, leading to a sphingolipidome pool of large structural
variation.7 This also raises questions as to how downstream
enzymes aer SPT are able to cope with the broad substrate
range, and how the biosynthesis of different types of SLs is
controlled.2.6 Sphingolipids and disease
Sphingolipids have been linked to a number of human diseases
and pathologies. These include Alzheimer's, cancer, diabetes
and various inammatory diseases.5 The molecular mecha-
nisms of these diseases and how they relate to sphingolipid
homeostasis and any disease-driven imbalance, is the subject of
current intensive studies.104,105 The genetic susceptibility to
a particular disease and the role that an individual's sphingo-
lipid “inventory” (determined by their specic biosynthetic
pathway) is also under investigation. An ideal scenario would be
a clear link between a specic gene mutation, an aberrant
enzyme activity and a resultant disease phenotype. However,
such clear cut links are rarely observed. Here we highlight theThis journal is © The Royal Society of Chemistry 2018current work on a rare neuropathy where mutations in SPT
provide a direct link between mutation, enzyme activity and
disease.
2.6.1 Deoxysphingolipids and the link to HSAN1. Muta-
tions in the genes encoding SPT have been associated with the
rare disease hereditary sensory and autonomic neuropathy type
1 (HSAN1).17 HSAN1 is an autosomal dominant disease that
results in progressive distal sensory loss and ulceration of the
limbs resulting from degeneration of dorsal root ganglia and
motor neurons.18,106,107 The link between HSAN1 pathology and
SPT has been hypothesised to be a consequence of a gain-of-
function of HSAN1 SPT mutants that can condense glycine or
L-alanine with acyl-CoAs108,109 (Fig. 9) to form ‘1-deoxy-3-ketos-
phinganine’ or ‘1-desoxymethyl-3-ketosphinganine’ (this inter-
mediate is only observed when ceramide synthase is inhibited
with fumonisin since deoxy-SLs are predominantly present in
the N-acylated form19). The lack of a C1 hydroxyl on LCBs
derived from these amino acids prevents the resulting so-called
“deoxy-SLs” from being phosphorylated by LCB kinases (1-
deoxysphinganine and 1-deoxysphingosine from L-alanine and
1-desoxysphinganine and 1-desoxysphingosine from glycine).
Phosphorylation of LCBs is required for the action of the lyase
enzyme responsible for the degradation of LCBs (see Section
5.0). As such, the resulting deoxy-SLs cannot be degraded by the
canonical degradation pathway and accumulate in membranes,
resulting in an ER stress response and cellular toxicity.108–111
There is evidence, however, that deoxy-SLs are metabolised by
a cytochrome P450 dependent pathway, which results in
hydroxylation and dehydration of the C14–C15 bond.112 Hor-
nemann and colleagues suggest this may be a deoxy-SL degra-
dation pathway (degradation products beyond these
hydroxylation and desaturation reactions are unknown) and
that a link between patients with type 2 diabetes and increased
deoxy-SLs may be due to downregulation of these enzymes.112
Evidence suggests that wild-type, functional SPT can form 1-
deoxy-LCBs under certain stress conditions such as impaired
glucose, lipid or amino acid homeostasis.113 That nature already
produces these “toxic” molecules is well known and has been
elegantly reviewed by Merrill.19 Briey, there are a number of
deoxys-SL natural products that have attracted great interest as
lead molecules in anti cancer therapy. For example, the clam-
derived compound spisulosine (Fig. 9a) is an inhibitor of cell
proliferation and triggers cell death pathways in several cancer
cell lines, with an anti-proliferative IC50 of 1 mM in prostate
tumour PC-3 and LNCaP cell lines.114–116 Similarly, enigmol
(Fig. 9b) is another sphingolipid analogue which can be
administered orally to mice and is toxic to a number of different
cell lines including colon cancer, and inmouse xenographs with
prostate cancer.117
2.6.2 HSAN1mutations in SPT1. To date 15 HSAN1-causing
SPT mutations (on both SPT1 and SPT2) have been identied in
patients from the USA, Europe and Australia (Table 2).118 HSAN1
patients display a wide range in age of onset of symptoms,
disease severity and clinical outcome. Historically, one of the
rst mutations found to cause HSAN1 was mapped in 2001 to
the SPT1 gene (located on chromosome 9) of HSAN1 patients in
both American and Australian families.17,18Nat. Prod. Rep.
Fig. 9 (A) Structures of deoxy-SLs formed from the condensation of palmitoyl-CoA with L-alanine (left) and glycine (right) forming ‘1-deoxy-3-
ketosphinganine’ from L-alanine and ‘1-desoxymethyl-3-ketosphingaine’ from glycine. These are reduced to 1-deoxysphinganine and 1-des-
oxymethylsphinganine respectively and then further metabolised to 1-deoxysphingosine and 1-desoxymethylsphingosine. It should be noted
that addition of the double bonds at C4 and C14 probably occurs to theN-acyl-deoxysphingoid base. (B) Structure of the natural product deoxyl-
SL enigmol.























































































View Article OnlineThe most common mutation was discovered to be due to
a single missense mutation of Cys133 to either a tryptophan or
a tyrosine (C133W or C133Y).18 Modelling studies based on the
structure of bacterial SPT suggested that Cys133 is located in
close proximity to the active site of the SPT1–SPT2 heterodimer,
across the subunit interface from the SPT2 lysine required for
PLP binding,39,59,90 and initial analysis suggested that pathology
arose from reduced activity of the SPT heterodimer.90 In an
important breakthrough, it was found that the HSAN1 muta-
tions reduced promiscuous SPT activity leading to increased
levels of toxic deoxysphingoid bases.109 In subsequent in vitro
experiments expressing the human SPT1C133W–SPT2–ssSPTa/
b heterotrimer in an S. cerevisiae spt1Dspt2D knockout, the
mutant SPT enzyme was shown to have 10–20% activity of the
wild type enzyme and in addition, produced C18-1-deoxy-
sphingolipids (with ssSPTa and ssSPTb) and C20-1-deoxy-
sphingolipids (with ssSPTb).111 When expressed in HEK293
cells, the SPT1C133W mutant gene was shown to cause an
increase in the levels of deoxysphingoid bases present.109 Hence
the C133W mutation allows SPT to catalyse condensation with
alanine, without altering the acyl-CoA specicity or signicantlyNat. Prod. Rep.altering affinity for L-serine. SPT1C133W–SPT2a–ssSPTa has a KM
of 1.4 mM for serine and 9.6 mM for alanine, whereas the wild
type enzyme has a KM of 0.75 mM for L-serine and does not
turnover alanine sufficiently to allow kinetic characterisation.111
Modelling of the C133W and C133Y mutations in S. pauci-
mobilis SPT (where human SPT1 Cys133 corresponds to bacte-
rial SPT Asn100) provides further insight into the structural
effect of these mutations (Fig. 10). Analysis of puried so called
“bacterial HSAN1 mutant mimics” (N100Y and N100W) caused
a blue-shi of the ketoenamine peak of the PLP cofactor, indi-
cating that the PLP binding environment is altered with respect
to the wild type enzyme. For both mutants, L-serine substrate
binding is diminished with respect to the wild type, as is the
catalytic efficiency using C16-CoA.59 Structural analysis of the
bacterial SPT N100Y mutant revealed that this mutant causes
signicant structural changes across the dimer interface, i.e.
a mutation in one monomer impacted on the other, analogous
to the human SPT1/SPT2 complex. So, it appears likely in the
human enzyme that the structural impact of the HSAN1
mutants may be to perturb the passage of information between
the monomers of the heterodimers.59 Interestingly one otherThis journal is © The Royal Society of Chemistry 2018
Table 2 Summary of HSAN1 causing mutations in the SPT1 and SPT2 subunits of SPT
LCB subunit Mutation Clinical effect Biochemical effect Ref.
LCB1 C133W Sensory neuropathy, ulceromutilations,
lancinating pains
Increased activity towards L-alanine (KM 9.6
mM), activity towards L-serine unaffected
(KM 0.75 mM for WT, 1.4 mM for mutant)
18, 109 and 111
LCB1 C133Y Sensory neuropathy, ulceromutilations,
lancinating pains
Increased levels of deoxysphingoid bases.
Reduced SPT activity
18, 109 and 111
LCB1 C133R Sensory neuropathy Increased levels of deoxysphingoid bases.
Reduced SPT activity
118
LCB1 V144D Sensory neuropathy, ulceromutilations,
lancinating pains
Decreased SPT activity 90, 109 and 110
LCB1 A310G Uncertain pathological signicance Unknown 123
LCB1 S331F Hypotonia, ulcerations, severe growth and
mental disability, vocal cord paralysis,
gastroesophageal reux
Increased levels of deoxysphingoid bases.
Reduced SPT activity
120–122
LCB1 S331Y As S133F Increased levels of deoxysphingoid bases.
Reduced SPT activity
120–122
LCB1 A352V Sensory neuropathy, ulceromutilations,
lancinating pains
Reduced SPT activity. Does not lead to
increased deoxysphingoid base levels in vitro
120 and 121
LCB1 G387A Not disease associated Not disease associated 122
LCB2 A182P Reduced sensation in the feet, sensory loss
and motor weakness
Increased levels of deoxysphingoid bases.
Reduced SPT activity. Increased activity vs.
alanine
124
LCB2 R183W Mild late onset progressive distal sensory
impairment
Elevated 1-deoxysphingolipid levels. No
effect on SPT activity
127
LCB2 V359M Sensory neuropathy, ulceromutilations Ambiguity towards amino acid substrate 126
LCB2 G382V Sensory neuropathy, ulceromutilations Ambiguity towards amino acid substrate 126
LCB2 S384F Reduced sensation in feet, shooting pains,
ulcerations and motor weakness
Reduced activity to L-serine, increased
activity to L-alanine
113
LCB2 I504F Sensory neuropathy, ulceromutilations,
osteomyelitis and anhidrosis
Ambiguity towards amino acid substrate 126























































































View Article Onlinemore recently-identied mutation at Cys133 in SPT1 which
leads to HSAN1 is C133R.119 The C133R phenotype was found to
be mild with respect to other Cys133 mutations, indicating the
biochemical features of this mutation may differ from that of
C133Y and C133W.119
In a similar fashion to the Cys133 mutations, SPT1 V144D
also decreases the enzymatic activity of the SPT1–SPT2 hetero-
dimer in a yeast model.90 A similar effect on activity was
observed when assayed in HEK293 cells overexpressing the
mutant enzyme. This was coupled with an increase in the levels
of deoxysphingoid bases in plasma.109,110 Val144 is predicted to
be close to the enzyme active site,39,59,90 and so mutations here
may affect the substrate binding capacity of the enzyme.
The most severe HSAN1 mutation identied is SPT1 S331F
which results in hypotonia, ulcerations, severe skeletal growth
defects and mental disability.120,121 Biochemically, decreased
enzyme activity is observed for the SPT1 S133F and S133Y
mutants in HEK293 cells, without a change in overall sphingoid
base levels.121,122 In S331F/Y patients, elevated levels of 1-deox-
ysphingoid bases are found in patient's plasma.121,122 Molecular
models using the bacterial SPT suggest that S331 is surface-
exposed and so consequently mutation of S331 could impact
on association with other proteins such as the small subunit or
regulatory proteins. Interestingly, Dunn and colleagues identi-
ed the S331F mutation in SPT1 as responsible for elevated
activity of the SPT1/SPT2 heterodimer. In addition, in contrastThis journal is © The Royal Society of Chemistry 2018to the wild type heterodimer, the mutant heterodimer was
activated better by ssSPTb than by ssSPTa.103 An SPT1 A352V
mutation also generates a HSAN1 phenotype and increased
levels of 1-deoxysphingoid bases in patients.120,121 Like Ser331,
Arg352 is predicted to be surface exposed. However, in vitro
analysis of the A352V mutation does not lead to an increase in
levels of 1-deoxysphingoid bases.120,121 In contrast to other
mutants, the SPT1 mutation, G387R, is said to be benign and
has no clinical effect, nor does it result in decreased activity in
HEK293 cells,110 whilst another, A310G, has been identied in
an HSAN1 patient, but the pathological effect is uncertain, as is
the effect on SPT activity.123
2.6.3 HSAN1 mutations in SPT2. Of the 15 HSAN1 muta-
tions identied so far, only 6 have been linked to the SPT2
subunit. Clinically, patients with an SPT2 A182P mutation
present with reduced sensation in the feet, sensory loss and
motor weakness.124 In vitro characterisation of the A182P
mutant showed 65% reduced activity compared to the wild type
enzyme and increased activity towards alanine. Additionally,
the mutant enzyme was shown to produce 1-deoxysphingoid
bases in vitro and elevated levels of 1-deoxysphingoid bases were
present in the plasma of patients.124 An HSAN1 mutation has
been identied at S384 (S384F),113 which is believed to be one of
two phosphorylation sites on SPT2 (in addition to Tyr387), as
shown by Olsen et al.125 The Ser384 mutant shows decreased
activity towards serine and increased activity to alanineNat. Prod. Rep.
Fig. 10 Modelling of the HSAN1 causing C133Y mutation of human
SPT in S. paucimobilis SPT (N100Y, PDB: 2W8W), highlighting the
structural changes which are proposed to affect the dimer interface
and loss of hydrogen binding interactions in the active site.























































































View Article Onlinecompared to the wild-type. In order to mimic the effect of
phosphorylation of the SPT2 subunit, Ernst and co-workers
created two other mutants, S384D (constitutively phosphory-
lated) and S384A (non-phosphorylated). Analysis of these
mutants showed that, like the S384F mutant, S384A had
decreased activity with L-serine but increased activity with L-
alanine, as well as increased levels of 1-deoxy SLs. The S384D
mutant behaved similarly to the wild-type enzyme, suggesting
that phosphorylation of Ser384 switches the substrate speci-
city of SPT from L-serine to L-alanine.
Finally, four other missense mutations have been identied in
SPT2.126,127 Three mutations occur at strictly-conserved residues,
V359M, R183W and G382V, and the fourth, I504F, is semi-
conserved across different species. When expressed in HEK293
cells, V359M, G382V and I504F were found to result in decreased
SPT activity and increased levels of deoxysphingoid bases.126
R183Won the other hand did not affect SPT activity, but did cause
increased levels of deoxy-SLs both in the patient and in vitro.127 In
vitro expression of SPT1–SPT2V359M/G382V/I504FssSPTa/b in yeast
lacking endogenous SPT revealed that the mutations did result in
changes to SPT activity.106 However, the effect was signicantly
less than observed for SPT1 C133W, C133Y and V144D mutants.
Using S. paucimobilis SPT as a structural model, the effects of the
V359M, G382V and I504F mutations were modelled in silico
(human SPT2 Val359, Gly382 and Ile504 map to bacterial SPT
V246, Gly268 and Gly385 respectively). The effects of these HSAN1
mutant mimics on bacterial SPT activity and structure are varied,
suggesting the each mutant displays subtle differences in
substrate binding and catalysis.106Nat. Prod. Rep.The debilitating impact of the various HSAN1-causing
mutations has driven clinicians, scientic researchers and
affected families to consider some therapeutic intervention to if
not cure, at least delay the onset of the disease. Since the
evidence suggests that the HSAN1 mutant SPT complex is
promiscuous and accepts L-alanine (and glycine) as well as L-
serine, it was suggested that oral administration of the natural
substrate L-serine could “compete out” this deleterious activity
and reduce circulating deoxy-SL levels below a toxic threshold in
various tissues. Initial results were promising enough to
undertake an NIH-funded clinical trial of this dietary supple-
ment in a small patient cohort (NCT01733407).128 If successful,
this simple pharmaceutical intervention could prove to be
a great example of personalised medicine. In a similar study
with a single Finnish female patient with the mild R183W
HSAN1 mutation in SPT2, dietary supplementation with L-
serine resulted in a robust lowering of 1-deoxy-SL levels and no
direct side effects.1292.7 SPT in other organisms (plants, C. elegans, kinetoplastid
parasites, apicomplexan parasites and Drosophila)
In this review we have chosen to concentrate on mammalian
and microbial SL biosynthesis. However, it is worth high-
lighting that other model systems from various species have
begun to bring out the similarities and differences in the genes,
enzymes, cellular compartmentalisation and regulation across
the various species.
In plants, just as in mammals and yeast, SLs are important
components of cell membranes, comprising up to 10% of plant
lipids.130 Plant SLs have been shown to be important for a host
of cell signalling pathways,131 such as stomata opening,132 low
temperature signalling133 and hypoxia response.134,135 A more
detailed overview of plant SL biosynthesis is provided in recent
reviews by Markham et al.8 and Michaelson et al.136
In the nematode worm Caenorhabditis elegans, SLs have been
found to be important in various cellular functions especially in
maintaining healthy and active mitochondria.137 In an elegant
study, RNA interference (RNAi), combined with drug-induced or
genetic disruption of mitochondria, led to the identication of
45 genes that were required to upregulate detoxication, relay
a pathogen response and manage mitochondrial repair path-
ways. Surprisingly, the screen identied C. elegans SPT and
other SL biosynthetic enzymes as playing roles in the surveil-
lance of mitochondrial damage. The expression of the C. elegans
SPT1-encoding gene was upregulated 2.5-fold by mitochondrial
damage suggesting that increased sphingolipid levels may acts
as a warning signal to the cell during mitochondrial disruption.
C. elegans live in a bacterial-rich niche and some microbes
antagonise mitochondria. In a more recent study, the unusual
iso-branched (iso-methyl C15 and C17, Fig. 11) structures of the
sphingoid bases from C. elegans were determined.138 These iso-
branched sphingoid bases did not support yeast mutant cells
lacking the ability to synthesise endogenous SLs. In C. elegans
RNAi mutants lacking SPT1, disruption to intestinal function
was observed, and only the natural iso-branched SLs, not deoxy-
iso-branched SLs, could rescue this phenotype.This journal is © The Royal Society of Chemistry 2018
Fig. 11 Structure of the C17 iso-branched sphinganine from C.
elegans.























































































View Article OnlineA recent study also investigated the SPT in the apicomplexan
parasite Toxoplasma gondii. This protozoan parasite has been
known to cause foetal damage and abortion in animals and
humans. This organism can synthesize SLs de novo and also
scavenge them from their host. For de novo synthesis, T. gondii
has evolved two highly-homologous SPTs (TgSPT1 and
TgSPT2).139 Bioinformatic analysis suggests that TgSPT1 and
TgSPT2 evolved via a gene duplication event (a single copy is
conserved in other Apicomplexa) aer horizontal gene transfer
from a prokaryotic species. Sequence analysis, combined with
biochemical assays on the recombinant SPTs revealed that
TgSPT1 is an active homodimer that displays the strongest
similarity to the microbial SPTs. The TgSPT is ER-bound but the
authors generated soluble protein by N-terminal truncation,
thereby increasing the probability of being able to determine
the structure of this unusual isoform, which, despite coming
from a eukaryotic parasite, bears the strongest resemblance to
the bacterial SPTs.
SPT activity has been identied the kinetoplastid parasite
Leishmania.140 Denny et al. showed that Leishmania major
contains homologs of both SPT1 and SPT2, similar to eukary-
otes. LmSPT2 is resident in the ER and essential for sphingo-
lipid biosynthesis (LmSPT2D mutants were severely growth
compromised). Interestingly, LmSPT2D mutants are unable to
differentiate into the infective forms of the parasite, suggesting
a role in infectivity.141 Moreover, analysis of inositol phosphor-
ylceramides using tandem mass spectrometry from L. major
indicates that the preferred substrate for LmSPT is myristoyl-
CoA. In contrast, the preferred substrate eukaryotes and the
kinetoplastid parasite Trypanosoma brucei is palmitoyl-
CoA.142–144
Similarly, the fruit-y D. melanogaster has also been investi-
gated as a model organism.145 The genome was sequenced and
analysis of the FlyBase identied many of the genes expected
from a SL biosynthetic pathway including SPT1 and SPT2,
although a number of other genes have so far not been anno-
tated. Taken together, these studies of alternative model higher
organisms will help to build up an evolutionary picture of the SL
pathway.
2.8 Inhibition of SPT
Due to the central role that it plays in the biosynthesis of SPT,
and the disease states which can arise from an imbalance of SL
homeostasis, SPT has been the subject of many studies to
identify inhibitors. Many inhibitors of SPT directly target the
PLP cofactor, and consequently are able to inhibit other PLP
dependent enzymes with a broad spectrum of activity. In this
review we focus on any natural products that have been shownThis journal is © The Royal Society of Chemistry 2018to be potent SPT inhibitors and useful tools for SL biosynthesis
in various organisms (Fig. 12).
One of the earliest SPT inhibitors identied was the
mechanism-based inhibitor L-cysteine.22,146,147 This amino acid
functions by mimicking the natural L-serine substrate; when in
the active site, cysteine forms a PLP:amino acid external aldi-
mine complex, but then readily reacts to form a ring-closed,
thiazolidine–PLP compound.21,148,149 This results in irreversible
modication of the PLP cofactor, rendering the enzyme non-
catalytic. The inhibitor L-penicillamine behaves in a similar
manner to cysteine by forming a thiazolidine adduct with the
PLP cofactor, inhibiting the enzyme. L-Penicillamine has also
been shown to inhibit other PLP enzymes such as alanine
aminotransferase and glutamate decarboxylase.150 D-Penicilla-
mine can also bind to the PLP cofactor, but is a weaker inhibitor
due to its inverse stereochemistry.151 Similarly, SPT can be
inhibited by D-serine, which forms an external aldimine which
cannot subsequently be deprotonated.152 Both D- and L-cyclo-
serine are irreversible inhibitors of SPT.45,153 There is evidence
that L-cycloserine inhibits SPT via a decarboxylative mechanism
of action which forms pyridoxamine 50-phosphate (PMP) and b-
aminooxyacetaldehyde which remain bound to the active site of
the enzyme.153
b-Chloroalanine (b-CA) is a well-known inhibitor of PLP
enzymes, which readily undergoes b-elimination of the chlorine
on formation of the substrate quinonoid.154 b-CA has been re-
ported to inhibit a number of different PLP enzymes, including
L-aspartate decarboxylase, D-alanine racemase and threonine
deaminase.154–157 In Chinese hamster ovary cells, complete
inhibition of SPT was seen with 5 mM b-CA in 10 minutes and
the halide analogue, b-uoroalanine can also be used to inhibit
SPT.158,159 Inhibition results in the formation of a PLP-bound
enamine species, which is liberated from the PLP cofactor by
attack from an active site lysine. The free enamine can then
react irreversibly with the lysine-PLP internal aldimine to create
a covalently bound inactive PLP complex, preventing further
catalysis. Halide inhibition has been reported for SPT.53 B.
melaninogenicus SPT was shown to be inhibited up to 60% by
25 mM NaCl. Conversely, no inhibition was seen with either
sodium or ammonium acetate up to concentrations of 600 mM.
Inhibition was also observed for bromide and iodide, but not
for uoride and for the pseudohalogen thiocyanate.
One feature of the natural product SPT inhibitors is their
structural resemblance to sphingosine; they have a long
hydrophobic tail with a polar head group. Lipoxamycin was rst
identied as an antifungal and antibiotic from the actinomycete
Streptomyces viginiae in 1971 and was subsequently shown to
inhibit SPT in 1994 with an IC50 of 21 nM against yeast
SPT.160–162 Lipoxamycin demonstrated broad range antifungal
activity and nanomolar toxicity against certain yeast strains
such as Candida. Inhibition could be reversed by the addition of
phytosphingosine in growth assays. Similar to lipoxamycin are
a set four of related natural products from Aspergillus fumigatus
termed sphingofungin A–D.163,164 Two further compounds,
sphingofungin E and F were isolated from Paecilomyces vari-
otii.165 Sphingofungins A, B and C were shown to be the most
effective compounds, with broad spectrum activity.Nat. Prod. Rep.
Fig. 12 Structures of natural product and synthetic inhibitors of bacterial and mammalian SPTs. Takeda and Lilly synthetic inhibitors are high-
lighted in curved and square boxes respectively.























































































View Article OnlineSphingofungin B was the most potent, with an IC50 of 20 nm
against S. cerevisiae.
Viridiofungins are a family of amino alkyl citrates (where the
amino acid is either tyrosine, phenylalanine or tryptophan)
isolated from Trichoderma viride.166,167 Viridiofungins are broad-
spectrum anti-fungal agents, exhibiting nanomolar potency
against Candida albicans, although potency against other fungi
such as S. cerevisiae was in the micromolar range, with vir-
idiofungin B being the most potent. Some structure–activity-
relationship (SAR) analysis has been performed on vir-
idiofungins and alterations to the acyl chain length, functional
group at C13 and oxidation state at C5/C6 did little to alter the
potency of the compounds.167 Conversely, the citric acid head
group and amino acid group were both required for activity.
Removal of the C1 methyl ester and the amino acid group
resulted in a 30-fold and 300-fold fall in activity, respectively.
However, the mechanism by which the viridiofungins inhibit
SPT is unknown.
The most widely used and studied natural product SPT
inhibitor is myriocin (also known as thermozymocidin).Nat. Prod. Rep.Myriocin was rst isolated in 1972 from Myrioccum albomyces
and Mycelia sterilia and shown to have anti-fungal activity. It
was then “re-isolated” from Isaria sinclairii due to its potent
immunosuppressive activity against lymphocyte proliferation in
mouse allogeneic mixed lymphocyte reactions (MLR).168–171 Also,
against mouse cytotoxic T lymphocyte cell lines (CTLL-2), myr-
iocin was discovered to have an IC50 of 15 nM and was found to
exclusively target SPT.172,173 SAR analysis by Fujita et al. showed
that the C14 carbonyl group is not required for activity.171
Reduction of this carbonyl group to an alcohol did not affect
activity, and its removal in fact increased potency. Lactonisation
of the C4 hydroxyl onto the carboxyl group did not perturb
activity, however, the amine group was found to be essential.
Finally, hydrogenation of the C6 double bond decreased
activity, as did ozonolysis of the alkene double bond. An
important investigation by Schreiber and colleagues conrmed
SPT to be the target of myriocin.173 In a pioneering study, they
generated a myriocin-affinity resin by coupling the natural
product via its acyl chain to a polymer support. Upon incuba-
tion of this “myriocin shing hook” to CTLL-2 cells theyThis journal is © The Royal Society of Chemistry 2018























































































View Article Onlinecaptured myriocin-binding proteins. Mass spectrometry
conrmed myriocin binds to both the SPT1 and SPT2 subunits
of SPT.
Structurally related to myriocin are two new recently
discovered natural product inhibitors of SPT, simplifungin and
valsafungin A and B, which were isolated from Simplicillium
minatense FKI-4981 and Valsaceae sp. FKH-53 respectively.174 All
three compounds inhibited the growth of zygomycetous fungi.
Derivatives of simplifungin and valsafungin were almost all less
effective antifungals than the parent compounds, with the
exception of a methylated derivative of simplifungin, which
gave MICs as low as 0.125 mg mL1 against S. cerevisiae. In vitro
against yeast microsomal SPT, IC50 values of 224 nM and
45.4 nM were reported for simplifungin and valsafungin A. This
compared with an IC50 of 11.8 nM for myriocin under the same
conditions and of 54.4 nM for the methylated derivative of
simplifungin.
The mechanism of action of myriocin has been studied in
some detail with SPT from various species but the most detailed
mechanistic study was carried out using S. paucimobilis SPT175
(Fig. 13). At rst glance it appears that the natural product
functions simply by forming an SPT:myriocin–PLP external
aldimine complex, in a mechanism similar to D-serine.
However, although this complex does form, and the Ki (967 nM)
was measured with a pure SPT for the rst time, the activity
cannot be restored through replacement of the PLP cofactor.
Instead, it was found that SPT catalyses the slow degradation via
an unexpected, retro-aldol like mechanism to give a PLP:D-
serine external aldimine and 2R,4Z,2-hydroxy-12-oxo-4-
octadecanal, which reacts irreversibly as a suicide inhibitor
with the active site lysine to form an imine. This imine, derived
frommyriocin breakdown, was identied by mass spectrometry
analysis of the inhibited SPT. Once this slow, enzyme-catalysedFig. 13 Proposed dual mechanism of inhibition of S. paucimobilis SPT
a retro-aldol like cleavage, resulting in an aldehyde that covalently modifie
external aldimine complex.
This journal is © The Royal Society of Chemistry 2018degradation had been discovered, it explained why X-ray
diffraction quality crystals of a SPT:myriocin–PLP complex
could not be obtained. Thus, a catalytically inactive SPT K265A
mutant was prepared and crystals were grown in the presence of
myriocin. Gratifyingly the structure of a SPT:myriocin–PLP
complex was resolved but even then, the myriocin was present
in a decarboxylated form. This surprising dual mode of inhi-
bition by myriocin on the bacterial enzyme revealed that SPT is
powerful enzyme that can degrade the most potent of inhibi-
tors. Whether the same mechanism is conserved across the
SPTs from various species is worthy of future study.
Recently, the results of several medicinal chemistry
campaigns against SPT have been reported.176–179 Using high-
throughput screening, Genin and colleagues discovered imi-
dazopyridine and pyrazolylpiperidine based compounds as
inhibitors of SPT.176 In vitro imidazopyridine had an IC50 of
5 nM against microsomal human SPT whilst pyrazolylpiper-
idine gave an IC50 of 64 nM. In mice, application of both
compounds led to a decrease in plasma ceramides, but resulted
in gastric enteropathy and so could not be pursued further.
Similarly, tetrahydropyrazolopyridine-derived compounds have
been reported by Yaguchi et al. and Adachi et al.177,178 These
compounds inhibited SPT in vitro and exhibit antitumor activity
against acute myeloid leukaemia non-small-cell lung cancer cell
lines. More detailed analysis of the mechanism of action
revealed that SPT inhibition resulted in an up-regulation of
COX-2 expression leading to cell death.179 The publication of
these results suggest that SPT is a potent and viable target for
novel therapeutics.
2.9 Regulation of SPT
The cellular ux and balance of the SL pathway is under very
tight control and allows cells to respond to the supply andby myriocin, in which the PLP:myriocin external aldimine undergoes
s the active site lysine (as a Schiff base) and formation of a PLP:D-serine
Nat. Prod. Rep.























































































View Article Onlinedemand for SLs and ceramides during growth, division and
apoptosis – the so-called “sphingolipid rheostat”. The links
between SLs and diseases continue to grow and SL regulation
has been the subject of intensive study. This area has been
reviewed recently.7,16,180–184 At a molecular level, the control of
the activities of the enzymes involved in the pathway (Fig. 1)
play an important role, but the exact details are still unclear.
Since SPT is the rst enzyme, pulling substrates from the L-
serine and acyl-CoA pools to generate 3-KDS, it is referred to as
the committed step in the pathway and it would make mecha-
nistic sense to have regulatory control at this key junction. The
issue of SPT regulation is a complex and active area of research.
Studies in yeast and mammalian cells identied the SPT-
activating Tsc3p and ssSPTs/b subunits respectively (Section
2.4) but subsequent studies have also identied additional
partners that play a role in SL regulation. These proteins, the
yeast ORMs (orosomucoid, 25 kDa) and their homologs in
higher eukaryotes, the ORMDLs (orosomucoid-like) were
discovered only recently. ORM proteins were rst identied in
yeast as transmembrane proteins localised to the endoplasmic
reticulum (ER). There are three 17 kDA ORMDLs in mammals
(ORMDL1, 2 & 3) whereas yeast have only two ORMs (ORM1 and
ORM2).185
2.9.1 ORMs in yeast. For some time aer their initial
discovery, the function of ORMs remained obscure and it was
not until 2010 that it was shown that yeast ORMs associate with
SPT, forming what is known as the “SPOTS” complex, consisting
of SPT1, SPT2, Tsc3p, ORM1, ORM2 and Sac1.10,186 By analysing
gene ontology data from yeast, Breslow et al. observed that
increased levels of ORM1 and ORM2 correlated with decreased
activity of SPT, implying that the ORMs are negative regulators
of SPT.187–189 Further evidence for a role of the ORMs in regu-
lating SPT came from the demonstration that they are physically
associated. This was achieved by FLAG-tagging LCB1 and per-
forming pull-down experiments.10 The isolated proteins were
identied by mass spectrometry. In contrast to the ORMs, theFig. 14 Proposed mechanisms of regulation of SPT under high and low
proteins are phosphorylated by a kinase, which prevents association with
non-phosphorylated, allowing interaction with TM1 of SPT1, inhibiting 3
Nat. Prod. Rep.role of the SPOTS partner, Sac1 – a phosphoinositide phos-
phatase, is somewhat mysterious. Sac family proteins have roles
in numerous cell functions, such as membrane trafficking,
however, the role of Sac1 in SL homeostasis and the reasons for
its association with SPT and the ORMs is unknown.190 Using
a different approach, Han et al. used ORM1 and ORM2 yeast
knockouts and observed a loss of SL homeostasis following
deletion of these genes. Since this phenotype could be reversed
by myriocin inhibition of SPT, it suggested that the ORMs
negatively regulate the activity of SPT. Additionally, over-
production of ORM2 in yeast results in decreased levels of SL
biosynthesis.191
Based on the work of Han et al. and Breslow et al., a putative,
basic working model of SPT regulation has emerged10,186
(Fig. 14). At high SL levels, SPT1, SPT2, Tsc3p, Sac1, ORM1 and
ORM2 exist in the “SPOTS complex” where association with the
ORMs results in inhibition of SPT activity, thereby blocking de
novo SL biosynthesis. The precise molecular mechanism by
which the ORMs inhibit SPT activity is unknown. However, the
ORM proteins have no known catalytic function, so inhibition
may result directly from binding. In yeast, the affinity of the
ORMs for SPT is regulated by phosphorylation of their N-
termini. At low SL levels, phosphorylation of the ORM
proteins results in their dissociation from the SPOTS complex,
releasing SPT and allowing SL biosynthesis to occur. Phos-
phorylation occurs at the N-terminus of the ORM proteins and
this leads to derepression of SPT, most likely by causing
a conformational change in the ORM protein. Since Sac1 is
a known phospho-lipid phosphatase which has been implicated
in the control of actin cytoskeleton and vacuole morphology, it
is unclear what direct role, if any, it has in SL homeostasis.192,193
The mechanisms by which the ORM proteins themselves are
regulated is also an active and complex area of research.
However, it is known that the ORMs are phosphorylated
through a kinase cascade involving Ypk1, TORC2 194 and
TORC1,195,196 possibly integrating signals from a number ofcellular SL levels in yeast. At low cellular SL concentrations, the ORM
and inhibition of SPT. However, under high SL conditions, the ORMs are
-KDS biosynthesis.
This journal is © The Royal Society of Chemistry 2018
Fig. 15 (A) Proposed mechanism of the NADPH-dependent, KDSR-
catalysed reduction of 3-KDS that converts the 3-keto group of 3-KDS
to give DHS. (B) Proposed topologies of Tsc10p (1 & 2) and FVT-1 (3 &























































































View Article Onlinedifferent pathways to control SL levels. Additionally, bio-
informatic studies have shown correlations between the ORMs
and other proteins, an example being the morphogenesis
checkpoint kinase Swe1.197,198 In yeast, Swe1 is able to regulate
SL biosynthesis independently of Ypk1, presumably via phos-
phorylation of the ORM proteins.
2.9.2 ORMs in higher eukaryotes. ORMDL family proteins
regulate SL biosynthesis in mammals and associate with SPT in
a similar manner to ORMs in yeast.10 ORMDLs came to prom-
inence when an association between asthma and single nucle-
otide polymorphisms in the region adjacent to the human
ORMDL3 gene locus were reported in 2007.183 These SNPs,
associated with an increase in the expression of ORMDL3
mRNA, are proposed to increase the risk to asthma through
perturbation of SL homeostasis.183,199–201
Like their cousins from yeast, the mammalian ORMDLs are
small, hydrophobic, transmembrane proteins approximately 17
kDa in size.185 However, unlike the ORMs, the ORMDLs do not
have an N-terminal tail region whose phosphorylation regulates
their inhibitory capacity. Consequently, the mechanisms by
which the ORMDLs control SL biosynthesis differ from the
ORMs. ORMDLs are functionally redundant and deletion of all
three isoforms is required to entirely abolish SPT regula-
tion.202,203 Similarly, it has been reported that overexpression of
all three ORMDL isoforms in HEK293 cells is required to inhibit
SPT activity.204
In a series of elegant experiments to investigate the regula-
tion of ORMDLs and SPT, Gupta et al. have made use of an SPT
overexpression cell line.205 Upon induction of SPT activity in an
HEK cell line, increased ORMDL expression is observed.
ORMDL induction is dependent upon SPT activity since over-
expression of a catalytically inactive SPT (SPT2 lysine mutant)
failed to induce expression of the ORMDLs, as did addition of
myriocin. As such, a product of SPT is in part responsible for
ORDML regulation. Gupta et al. also noted that inhibition of
ceramide synthase activity via the inhibitor fumonisin also
reduced levels of ORMDL. This supports observations by Siow
and Wattenberg that a complex SL downstream of ceramide is
responsible for ORMDL induction.202
Based on published data, it is apparent that ORMDL
expression is not regulated by one single factor but through
a complex regulatory mechanism which is still being deci-
phered, although there is as yet no evidence for any post-
translational modications.205 Beyond the observation that
ORMDL expression changes in response to an as-yet unknown
complex SL, it is unclear whether each ORMDL isoform is
responding to the same signal or whether ORMDL control of
SPT simply occurs by binding to the enzyme.
An additional layer of complexity is added by phosphory-
lation sites on human SPT. Taouji et al. identied Tyr164 as
a phosphorylation site of SPT1.206 Phosphorylation of Tyr164
is mediated by the tyrosine kinase ABL and increases SPT
activity. Another such phosphorylation site has been identi-
ed on the SPT2 subunit, Ser384.113,125 Phosphorylation of
Ser384 caused a decrease in activity towards L-serine.
However, increased activity towards L-alanine was alsoThis journal is © The Royal Society of Chemistry 2018observed. The physiological signicance of SPT phosphoryla-
tion remains to be determined.
3 3-Ketodihydrosphingosine
reductase (KDSR)
The second enzyme on the committed pathway to SL biosyn-
thesis is 3-ketodihydrosphingosine reductase (3-KDSR), which
catalyses the NADPH-dependent reduction of 3-KDS to give
sphinganine (2S,3R-dihydrosphingosine (DHS)) (Fig. 15a). 3-
KDSR was rst identied by Dunn and co-workers in Saccha-
romyces cerevisiae using a temperature/calcium sensitivity
screen looking for genes encoding enzymes involved in SL
biosynthesis.207 Tsc10p was found to belong to a large super-
family of enzymes known as the short chain dehydrogenases/
reductases (SDR) and when expressed in vitro was shown to4) within the ER membrane.
Nat. Prod. Rep.























































































View Article Onlinecatalyse the NADPH dependent reduction of 3-KDS. Tsc10p has
been subsequently characterised in two other microbial strains,
Candida albicans and Aspergillus fumigatus, and identied in
a number of different strains through sequence similarity.208
KDSR has been identied in Arabidopsis,209 and using yeast
complementation assays, a Tsc10p homolog has been found in
mammals, FVT-1, which exhibits 24% identity and 42% simi-
larity with Tsc10p.210
Yeast Tsc10p (320 aa, 36 kDa) contains a 28 amino acid C-
terminal stretch which is proposed to anchor and direct the
enzyme to the ER membrane (Fig. 15b). Removal of this C-
terminal stretch is not deleterious to protein activity, suggest-
ing that Tsc10p contains a hydrophilic N-terminal catalytic
domain. Human FVT-1, on the other hand, is proposed to
contain three trans-membrane regions, with the N-terminal
trans-membrane region facing the ER lumen and the C-
terminus facing the cytosol. The transmembrane N-terminal
region is required for targeting of FVT-1 to the ER membrane.
A large hydrophilic domain, which contains the proposed active
site, is thought to face the cytosol. It has been suggested,
however, that the transmembrane regions in FVT-1 and Tsc10p
may not span the entirety of the membrane, and may merely
constitute a hydrophobic domain which embeds into the
membrane.211 Both Tsc10p and FVT-1 are multimeric, as shown
by immunoprecipitation experiments.
All four functionally characterised KDSRs (S. cerevisiae, H.
sapiens, C. albicans and A. fumigatus) share conserved serine,
threonine and lysine residues (based on S. cerevisiae
numbering; Ser167, Tyr180 and Lys184), corresponding to the
catalytic triad of residues found in SDRs and the TGxxxGxG
motif at the N-terminus for coenzyme binding.212,213 Opper-
mann and colleagues have shown that SDRs likely have, in fact,
a catalytic tetrad incorporating Ser167, Tyr180, Lys184 and
Asn140.214 However, sequence alignment of the four enzymes
discussed here shows that the Asn140 residue is not conserved
in A. fumigatus (replaced with a valine). Using the structures of
related short chain dehydrogenases, Fornarotto and co-workers
have constructed a homology model of 3-KDSR from A. fumi-
gatus.208 Docking of the 3-KDS and NADPH substrates into the
homology model suggests that the majority of the 3-KDS
substrate is not involved in binding to the enzyme active site,
and protrudes into the solvent. The enzyme active site is
proposed to be at the C-terminus of the enzyme, close to the
membrane associating helix, allowing the hydrophobic
substrate to embed within themembrane. Given this potentially
broad substrate specicity, a variety of shortened 3-ketos-
phinganine analogues were screened against A. fumigatus 3-
KDSR. Interestingly, C8, C11 and C12 analogues were all turned
over by the enzyme (monitoring NADPH consumption), albeit
with diminished Km and kcat values.
Yeast Tsc10p knockouts are not viable, indicating that
Tsc10p is the only 3-KDSR in the yeast genome. However, in
mammalian genomes, the presence of orphan SDRs means that
FVT-1 may not be the only 3-KDSR enzyme present. Interest-
ingly, siRNA experiments in CHO cells indicate that FVT-1 is the
major enzyme responsible for 3-KDSR activity in mammals.
Given the differences in topology between FVT-1 and Tsc10p, itNat. Prod. Rep.is remarkable that FVT-1 is able to rescue Tsc10p knockouts,
and suggests there are several mechanisms in yeast for targeting
proteins to the ER membrane.211 A detailed mechanistic
understanding of how any KDSR controls the stereochemical
outcome that leads to formation of the 2S,3R diastereomer of
DHS will require a high resolution crystal structure of the
enzyme:substrate complex. Moreover, since the discovery of the
deoxy-SLs, it is apparent that the KDSRs and subsequent
downstream enzymes can accept deoxy derivatives of 3-KDS for
reduction. Of note is the apparent lack of association between
SPT and KDSR. SPT immunoprecipitation experiments have not
pulled down KDSR,10 so it is unknown whether SPT simply
deposits 3-KDS into the membrane for KDSR ‘to nd’, or
whether there is some channelling of the substrate.3.1 Disease associated mutations in KDSR
Mutations in the KDSR gene have been associated with a small
number of disease states in cattle and humans. In cattle, bovine
spinal muscular atrophy (SMA) is a recessive neurodegenerative
disease which causes loss of motor neurons.215 Mapping of the
SMA locus led to the FVT-1 gene, where a missense G-to-A
mutation was found, resulting in a A175T mutation. In vitro
analysis of the recombinant bovine FVT-1 protein (truncated by
the rst 25 residues to remove a putative transmembrane
domain) revealed that the mutant enzyme displays no activity.
Interestingly, in an S. cerevisiae tsc10D knockout, expression of
FVT-1 and the FVT-1 A175T mutant resulted in the same growth
phenotype, indicating that although no activity can be detected
in vitro, in vivo there may be some residual activity. Although the
molecular cause of this loss of activity is unknown, bovine
Ala175 is very close to Ser173, which correlates to Tsc10p
Ser167, a conserved residue of the catalytic triad. As such, the
bovine A175T mutation may disrupt the catalytic triad, pre-
venting catalysis.
In humans, mutations in KDSR have recently been associ-
ated with an array of keratinization disorders (skin disor-
ders).216,217 These two separate studies performed exome
sequencing and found a variety of different mutations in the
KDSR gene, including gene inversions, base pair deletions and
substitutions. The deletion mutations identied likely lead to
exon skipping or frame shis, resulting in catastrophic effects
on the protein structure. In one case, the conserved catalytic
tyrosine is mutated (Y186F), preventing catalysis. In vivo assays
using an S. cerevisiae tsc10D knockout showed that expression
of the majority of the mutant genes failed to complement the
tsc10 knockout, demonstrating the deleterious effects of these
mutations on enzyme activity. The only exception was a F138C
mutation, which was found to have a mild effect in vivo. Take-
ichi et al. analysed a number of the mutations in vitro using
microsomal preparations of HEK293 cells. In a similar result to
the in vivo yeast assay, all but one mutation abolished KDSR
activity. Interestingly one mutation, G182S, did not lead to
a signicant loss in DHS production, which is unexpected given
that Gly182 lies in a hydrophobic domain in close proximity to
the active site tyrosine and would be predicted to lead to
structural changes in the protein. However, without a highThis journal is © The Royal Society of Chemistry 2018























































































View Article Onlineresolution structure of human KDSR, it is difficult to explain
conclusively in molecular terms the effect of these mutations on
the catalytic activity.4 Sphingosine kinase (SK)
Sphingosine kinases (SKs) are ATP dependent kinases of the
diacylglycerol kinase (DAGK) family, which phosphorylate the
terminal hydroxyl group of sphingoid bases – either sphinga-
nine (from de novo synthesis) or sphingosine (from ceramide
breakdown). Sphingosine, the long chain base derived from
ceramide hydrolysis, is phosphorylated by SK to give sphingo-
sine 1-phosphate (S1P). S1P is an important signalling molecule
both inside and outside of the cell, where it binds to S1P-
specic G-protein coupled receptors triggering a cascade of
SL-dependent cellular events.16 Given its central role as a second
messenger, changes in S1P homeostasis have been linked to
diseases such as cancer and diabetes.218–222 The biological
function and regulation (for example palmitoylation and
phosphorylation) of the protein of S1P and SK is a large,
complicated and intensively active area of current research.223
As such, these topics will not be discussed here. Rather the
interested reader is directed to several excellent reviews in the
area.224–227
In mammals, SK is encoded by two genes, each of which
give rise to multiple splice variants,228–230 which differ in the
length of their N-terminal domain.229,231–233 Whilst SK1 (also
termed SPHK1) is mostly cytosolic, SK2 (also termed SPHK2)
is predominantly found within the nucleus and has a largeFig. 16 3D structure of human SK1 homodimer with the inhibitor SKI-II/A
binding site is highlighted, showing the residues required for substrate b
This journal is © The Royal Society of Chemistry 2018insert in the lipid binding domain.234–237 The SK isoforms also
differ in their tissue distribution and in their substrate
specicities. Although both have similar specicities for the
natural D-erythro-sphingosine substrate (KM of 3.4 mM), SK2
has an increased specicity for D-erythro-dihydrosphingosine,
DL-threo-dihydrospingosine and phytosphingosine.
Conversely, D-erythro-sphingosine was the best substrate for
SK1.230 Neither SK1 nor SK2 phosphorylates ceramides but
a specic ceramide kinase has been discovered238 and
cloned.239,240 SK1 has also been reported to accept GTP as
a nucleotide substrate as well as ATP, albeit with a signi-
cantly reduced preference241 The immunosuppressive drug
FTY720 (Fingolimod, Gilenya™, see below) sold by Novartis to
treat multiple sclerosis is, in fact a “pro-drug” that is phos-
phorylated by SK1 and SK2.233,242,243
Despite this difference in substrate preferences, SK1 and SK2
are functionally redundant.230,244 Either SK1 or SK2 can be
knocked out inmice, and result in viable progeny.245,246 A double
SK1 and SK2 mutant however, is not viable.246 Interestingly,
overexpression of either SK1 or SK2 in mice has opposing
effects. Overexpression of SK2 increased incorporation of [3H]-
palmitate into C16 ceramide, whereas overexpression of SK1
decreased incorporation.236 This indicates that the two SK iso-
forms have contrasting functions in the homeostasis of
ceramide biosynthesis. SK homologs have been identied in
Leishmania major and Trypanosoma brucei.247,248 In T. brucei SK
has been shown to be important in controlling the cell cycle
whilst in L. major, SK is responsible for detoxication of
sphingoid bases and regulating the stress response.DP bound (PDB: 3VZD) and sphingosine bound (PDB: 3VZB). The ADP
inding, provided by both subunits.
Nat. Prod. Rep.























































































View Article Online4.1 Structure of SK1 (SPHK1)
The SK proteins are unusual amongst the SL biosynthesis
enzymes as they are not integral membrane proteins. Rather,
SKs associate with the plasma membrane when activated via
a process which is related to their regulation (reviewed in Pyne
et al.224). Despite being cloned in 2000 228 it was surprising that
the crystal structure of human SK1 was only reported by Amgen
in 2013.249 The overall 3D structure was novel and bears no
similarity to other previously-characterised protein or lipid
kinases. The structure revealed a two domain enzyme split into
N- and C-terminal halves (Fig. 16).249 The C-terminal domain
consists of the sphingoid base binding site and has a mainly
antiparallel b-sandwich architecture. The sphingosine substrate
is proposed to bind in a J-shaped conguration, with the polar
head group held in place in the inter-domain cle through
hydrogen bonding with Asp81 and Ser168. Wang et al. reported
electron density which could not be assigned to detergents used
in crystallography, and thus it is suggested that this density is
due to a C16 long-chain base retained by the enzyme through
purication. The hydrophobic tail of sphingosine then sits in
a J-shaped hydrophobic pocket. This hydrophobic pocket is,
however, almost completely buried within the enzyme, and is
only accessible through a hydrophilic opening in which the
sphingosine head group sits. Comparison of the structures of
the substrate-bound and ligand-free SK1 structures reveals
a side opening in the enzyme. Wang et al. also suggest that two
a-helices (a7 and a8) might act as a gate, and control binding of
the sphingosine substrate through this side gate, allowing
access to the active site.
The catalytic site of SK1 is found at the cle between the N-
and C-terminal domains. The N-terminal domain itself consists
of an a/b fold and encompasses the binding site for the nucle-
otide substrate. Crystals grown in the presence of ADP reveal
that the nucleotide binds in this cle and the b-phosphate of
ADP bridges the N- and C-terminal domains. A multitude of
interactions are required for binding, including hydrogen
bonding, p-stacking interactions and coordination to a Mg2+
cofactor.249,250 A recent study by Pulkoski-Gross et al. used
hydrogen–deuterium exchange mass spectrometry to identify
a positively charged motif on the surface of SK1 which is
responsible for binding to membranes via anionic phospho-
lipids, and regulating the correct function of the enzyme.251Fig. 17 (A) Structures of the SK inhibitors PF-543 and SKI-II. (B)
Mechanism of phosphorylation of sphingosine by SK1.4.2 Mechanism and inhibition of SKs
Since SK1 is a drug-discovery target, the determination of the
crystal structure of human SK1 helps rationalise the medicinal
chemistry programmes that seek to exploit this key enzyme. A
number of small molecule compounds have been reported as
inhibitors of SKs (as reviewed by Santos & Lynch,252 Sanlleh́ı
et al.253 and Pitman et al.254), the majority of which target the
sphingosine binding site. Due to the large number of inhibitors
reported, we will only focus on those whose structures have
been characterised in complex with SK1. A number of
sphingosine-like compounds act as inhibitors including N,N-
dimethyl-sphingosine (DMS)241,255 and DL-threo-dihy-
drosphingosine.256,257 However, other small molecules, notNat. Prod. Rep.structurally related to sphingosine have also been re-
ported.225,252 SK1 was rst crystallised in the presence of the
inhibitor SKI-II (Fig. 16a), a known SK1 and SK2 inhibitor with
antitumor activity.249,258,259 SKI-II binds in the hydrophobic
pocket of SK1, where the hydrophobic chain of a lipid (believed
to be sphingosine) is bound, suggesting SKI-II is a competitive
inhibitor of the SKs. The inhibitor is held in place by a series of
hydrogen bonds, van der Waals interactions and hydrophobic
interactions. A crystal structure in the presence of PF-543
(Fig. 17a, the most potent SK inhibitor reported to date) has
been reported.237,260 Like SKI-II, PF-543 binds in the lipid
binding pocket of the enzyme in a bent conformation. This bent
orientation somewhat resembles that of the “sphingosine” re-
ported in the structure of SK1 by Wang et al.249 Likewise, PF-543
binds through a series of hydrophobic interactions and
hydrogen bonds. Interestingly, the hydroxymethyl moiety of PF-
345 binds adjacent to the ATP binding site, apparently
mimicking the polar head group of sphingosine.
Mechanistically, SK catalyses the transfer of the g-phosphate
from a molecule of ATP onto the C1 hydroxyl group of sphin-
gosine (Fig. 17b). The catalytic mechanism begins with depro-
tonation of the C1 hydroxyl, which then attacks the phosphate
group of ATP, giving ADP and phosphorylated sphingosine as
products. Some questions remain with regards to the base
responsible for deprotonation with Asp81 proposed to play this
role.249 In addition, Asp81 is also believed to be involved inThis journal is © The Royal Society of Chemistry 2018























































































View Article Onlinehydrogen bonding to the cap of helix a5. Involvement of Asp81
may require movement of the enzyme during substrate binding
and catalysis.225 With the 3D structure of the human SK1 in
hand, we would expect similar molecular analysis of SL kinases
from other species to follow. As well as laying a foundation for
future drug discovery, the SK structures will also provide insight
into kinase regulation and translocation by factors such as
calmodulin.261Fig. 18 Structures of the S1PL substrates sphingosine 1-phosphate,
sphinganine 1-phosphate, phytosphingosine 1-phosphate and sphin-
gosine 1-phosphonate.5 Sphingosine 1-phosphate lyase
(S1PL)
Both SPT, the rst enzyme that controls entry to SL biosyn-
thesis, and sphingosine-1-phosphate lyase (S1PL), the nal
enzyme that regulates exit from the SL pool, are PLP-dependent
enzymes. S1PL catalyses the retro-aldol like cleavage of S1P to
hexadecenal (2E-HEX) and phosphoethanolamine (PEA), both
of which are substrates which feed into glycerophospholipid
synthesis262 and the former of which has been demonstrated to
have signalling function (Fig. 2).12,263 In theory, this S1PL-
dependent reaction is reversible, but to date, no conversion of
2E-HEX and PEA to S1P has been described. This effectively
makes the S1PL-catalysedmetabolism of S1P irreversible, acting
as a release valve to maintain a SL balance.
S1PL, like SPT, is a type 1 PLP enzyme rst identied in S.
cerevisiae (where it is termed Dpl1p and BST1) by Saba et al. in
1997, with identication of the human homologue following
three years later.12,220 In yeast, S1PL function has been impli-
cated in a variety of different processes such as heat stress and
nutrient deprivation.264,265 Deletion of S1PL in yeast by Saba was
found to result in a severe sensitivity to sphingosine, with
cellular growth inhibited at micro molar concentrations of
exogenously added sphingosine, likely due to the inability of the
deletion strain to remove SL from the cell.220
Human S1PL shows a high degree of substrate stereospeci-
city (Fig. 18), only accepting substrates of D-(+)-erythro
conformation.12 This stereospecicity likely reects the need to
correctly position the C2 amine to react with PLP and to posi-
tion the C3 hydroxyl to interact with an active site base.
However, S1PL from rat liver extracts is signicantly less
regiospecic and can cleave a variety of different sphingoid
bases including S1P, sphinganine 1-phosphate, phytosphingo-
sine 1-phosphate and sphingosine 1-phosphonate.266 However,
S1PL cannot turnover sphinganine. As such, the phosphate
group is essential for binding. However, modications to the
head group are tolerated. For example, sphinganine 1-phos-
phonate is also accepted by S1PL in rat liver extracts, but at
a diminished rate,267 indicating that both the phosphate head
group and the hydrophobic tail are necessary, but not sufficient,
for binding. Mouse S1PL is tolerant towards modications to
the acyl chain, such as C4 or C5 methylation.268 In the case of
S1P, the geometry of the C4 olen did not alter activity. Activity
towards substrates with acyl chain lengths as short as C7 and as
long as C20 has been reported.269,270
Given the important functions that S1P performs in the cell,
S1PL therefore has an important role in controlling cellularThis journal is © The Royal Society of Chemistry 2018levels of this signalling molecule. However, understanding the
biochemistry of yeast and mammalian S1PL homologs is
hampered by their association with the ER membrane and the
insolubility of substrate. A soluble homologue of S1PL is
present in the thermophilic bacteria Symbiobacterium thermo-
philum.271 Sequence alignment of the S. thermophilumwith other
S1PL sequences (yeast, human) reveals that it lacks the trans-
membrane domain, likely contributing to its solubility.
5.1 Structure of S1PLs
Taking advantage of its inherent solubility, the S. thermophilum
S1PL homolog (StS1PL) was the rst to be crystallised (Fig. 19).
It is a homodimeric enzyme, displaying a characteristic 3D fold
shared with other type I PLP enzymes.271 The structure of an
StS1PL subunit can be divided into four regions: an N-terminal
domain (which is disordered, termed the Nt-FLEX domain),
a central catalytic domain, a C-terminal domain and a C-
terminal extension domain. As is the case with SPT, the active
site is found at the subunit interface and residues from both
subunits are required to form the active site. Interestingly, two
conformations of StS1PL were crystallised. One structure was
symmetrical whilst the other asymmetrical. In the asymmetrical
St1SPL conformation, one of the active sites lacks the PLP
cofactor, whilst in the symmetrical StS1PL, both active sites
contain the PLP cofactor. Moreover, the asymmetric and
symmetric conformations had varying levels of disorder within
the C-terminal extension, with the C-terminal domain in the
asymmetric StS1PL being completely disordered. This asym-
metric form is somewhat similar to human and yeast SPT, in
which there is believed to be only one active site (see Section
2.0).
The enzyme active site is centred around the PLP cofactor
and contains residues from both subunits. A long hydrophobic
tunnel extends from the surface of the protein to the active site.Nat. Prod. Rep.
Fig. 19 3D structures of S1PLs from B. pseudomallei, S. cerevisiae and S. thermophilum. The internal aldimine (PLP cofactor covalently bound to
Lys311) and product external aldimine (PLP–PEA non-covalently bound to the K311A mutant) forms of S. thermophilum are also shown,
highlighting the residues involved in substrate binding and catalysis.























































































View Article OnlineSpecically the PLP cofactor forms an imine with lysine 311 and
the pyridine ring is positioned between histidine 201 and
cysteine 276 (Table 3, Fig. 19). The PLP phosphate is bound by
a classical phosphate binding cup, again comprising residues
from both subunits. A crystal structure of the K311A StS1PL
mutant with the product PEA reveals that a pocket of residues
comprising Tyr105 and Ala103 of one subunit and Asn126 and
His198 from the adjacent subunit is required for binding of the
phosphate of the substrate.
In S. cerevisiae, Dpl1p is bound to the ER membrane by
a single-pass transmembrane domain on the N-terminus of the
protein.266,272,273 The N-terminal domain faces the ER lumen and
is glycosylated, whilst the active site is located on the cytosolic
face of the protein in a large soluble domain. Dpl1p forms
hetero-oligomeric structures. Interestingly, the formation of
these SPL oligomers is dependent upon the transmembrane
region. Removal of the transmembrane region similarly results
in a loss of protein activity. This is likely due to the fact that the
active site is at the dimer interface, utilising residues from both
subunits.260
The structure of Dpl1p (lacking the rst 102 residues corre-
sponding to the transmembrane region, termed Dpl1p D1–102)
was reported at the same time as the structure of StS1PL.271
Analysis of the Dpl1p structure reveals that it is strikingly
similar to the S. thermophilum enzyme, and shares the disor-
dered N-terminal domain. The analogous residues to those
found in StS1PL involved in the PLP phosphate binding cup,Nat. Prod. Rep.PLP binding and substrate binding are listed in Table 3. Inter-
estingly, Dpl1p D1–102 was inactive in vitro, which is believed to
be due to the disorder on the C-terminal extension. It is
proposed that the transmembrane domain (residues 1–102) is
required for stability of the C-terminal extension, which is in
turn required for substrate penetration to the active site.
Mutation of certain key yeast S1PL residues identied in the
crystal structure (K380, Y174, A172, H198, C344, K386 and Y554)
believed to be required for function has no effect on the viability
of yeast in in vivo phytosphingosine sensitivity assays.271
However, mutation of residues Lys380, Ala172, and Lys386 was
found to abolish S1PL activity, preventing yeast growth. Residue
Lys380 is required for PLP binding, and so it is unsurprising
that it is essential for activity. Ala172 is proposed to be involved
in binding of the substrate phosphate moiety. Bourquin et al.
mutated this residue to a proline, resulting in inactivated
protein. It is unclear whether this mutation is in fact essential
for activity, or whether the proline residue could possibly have
introduced a turn into the structure, thus resulting in a mis-
folded, inactive protein. Lys359 meanwhile is believed to elec-
trostatically contribute to binding of the substrate phosphate
moiety. Consequentially mutation of this residue may prevent
substrate binding. Mutation of residues Cys344, Tyr174, His198
and Tyr554 was found to be less deleterious, but resulted in
signicantly less healthy yeast. Tyr554 is believed to be impor-
tant for substrate accommodation in a hydrophobic pocket,
whilst His198 and Tyr174 are required for substrate binding.This journal is © The Royal Society of Chemistry 2018
Table 3 Summary of key residues in S1PL enzymes across different species. Residues marked with * are provided by the adjacent subunit
(Proposed) role
Organism
StS1PL Dpl1p HsS1PL PlS1PL BsS1PL
PLP phosphate binding cup G168 G235 G210 G220 G126
T169 T236 T211 T221 T127
H310 H379 H352 H359 H270
S353* S422* S395* S402* S313*
PLP sandwich C276 C344 C317 C328 C235
H201 H268 H242 H252 H159
Substrate phosphate binding Y105 Y174 Y150 Y160 Y58
H129* H198* H174* H185* Q82*
A103 A172 T148 A157 T56
N126* N195* N171* N182* N79*
K317 K386 K359 K366 K277
PLP binding K311 K380 K353 K360 K271
PLP aspartate D274 D342 D315 D326 D233
Substrate entry Y482 Y554 Y526 Y543 Y442























































































View Article OnlineCys344 is believed to perform a structural role, assisting in
maintaining the orientation of the PLP cofactor.
Homologs of S1PL have been discovered in various other
organisms including the microbial species and intra-cellular
pathogen Legionella and the trypanosomatid protozoan Leish-
mania. In L. major, deletion of S1PL allows the organism to
grow, but it is defective in stationary phase and virulence.274 In
contrast to Leishmania, which produce sphingolipids and have
the enzymes required for SL biosynthesis,275 Legionella appears
to lack SLs and the other genes of the de novo SL biosynthetic
pathway. Therefore, this observation raises the question as to
what role(s) SLs play in these organisms. The L. pneumophila
S1PL (LpS1PL) displays sequence homology with the yeast (28.4
identity, 43.7% similarity), human (30.2% identity, 46% simi-
larity) and S. thermophilum (27.9% identity, 41.2% similarity)
enzymes and was isolated by Rolando et al.276 In LpS1PL,
mutation of residues Cys328 and lysine 366 resulted in
decreased enzyme activity. Cys328 is analogous to Cys344 in
Dpl1p whilst Lys366 is analogous to Lys380. It is interesting that
the lysine residue is essential for activity in Dpl1p whilst it is not
essential in LpS1PL. A structure of the enzyme, albeit without
the essential PLP cofactor, allowed comparison of the bacterial
and human S1PLs. This study also showed that Legionella can
reduce the host SLs in a S1PL-dependent mechanism. This work
suggests that in pathogens S1PL plays a role in virulence and
provides a link between SLs and autophagy.
The role that S1PLs play in microbial pathogenicity was
recently investigated in various strains of Burkholderia. These
organisms do not encode SL biosynthesis genes but genome
analysis revealed that Burkholderia pseudomallei K96243,
a category B biothreat agent, encodes two homologous proteins
(S1PL2021 and S1PL2025) that display moderate sequence
identity to known eukaryotic and prokaryotic S1PLs.277,278 Both
homologs were isolated and shown to catalyse S1PL-dependent
conversion of S1P to 2E-HEX and PEA using a convenient fatty
aldehyde dehydrogenase (FALDH) dependent coupled assay.
The crystal structure of the B. pseudomallei S1PL2021 (Fig. 19,
Table 1) was determined with the PLP cofactor bound. This
enzyme displayed structural similarity to other S1PLs and, inThis journal is © The Royal Society of Chemistry 2018the absence of a substrate or inhibitor, the authors propose
a substrate-binding funnel that binds S1P. It will be interesting
to screen inhibitors known to target the human S1PL as anti-
microbial agents.253 The unexpected appearance of two copies
of highly homologous S1PLs (possibly generated by gene
duplication) in the Burkholderia was investigated by deletion
studies, phenotypic analysis and macrophage survival. The
S1PLs of B. thailandensis (BTH_II0309 and BTH_II0311) func-
tionally complement S1PL-decient yeast. Furthermore, S1PL
knock out studies of both Burkholderia strains showed that the
S1PLs are required for virulence in both Galleria moth and
murine models of infection. These combined studies conrm
a strong link between S1PL-dependent SL metabolism and
virulence, but the reasons why Burkholderia in particular encode
two S1PL copies requires further study.5.2 Mechanism and inhibition of S1PL
Very few specic inhibitors of S1PL have been reported in the
literature to date. Non-specic inhibitors of S1PL activity
include metal ions (Ca2+, Zn2+), N-ethylmaleimide and iodoa-
cetamide.22,266 Additionally, S1PL can also be inhibited by the
2D-, 3L-isomer of sphinganine and by sphinganine 1-phospho-
nate.267,279 The inhibitor FTY720 (an S1P receptor agonist
derived frommyriocin via a medicinal chemistry programme,280
Fig. 20a), used as an immunomodulatory agent, can inhibit
S1PL in vitro. Thymic extracts from mice following treatment
with FTY720 also showed inhibited SPL activity.281 Two other
functional SPL inhibitors identied include deoxypyridoxine
and 2-acetyl-4-tetrahydroxybutylimidazole.282,283
Specic S1PL inhibitors have been published alongside the
structure of human S1PL. Human S1PL was crystallised in the
absence of the transmembrane region corresponding to resi-
dues 1–61.284 The overall structure is similar to that of StSPL and
Dpl1p. The key active site residues (as discussed for StSPL) are
listed in Table 3. Of note is the fact that the StSPL was crystal-
lised in the presence of an SPL inhibitor, (R)-6-(4-(4-benzyl-7-
chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile,
(Fig. 20a).285 This compound binds at the entrance of the tunnelNat. Prod. Rep.
Fig. 20 (A) Structure of FTY720 and the S1PL inhibitor (R)-6-(4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile. (B)
Proposed mechanism of S1P cleavage by S1PL, which involves the retro-aldol like cleavage of S1P.























































































View Article Onlineleading from the surface of the protein to the active site,
approximately 5 Å from the active site. This tunnel is composed
of hydrophobic residues required for substrate binding and
thus it is unsurprising that this is the binding site of the
inhibitor.284
Since S1PL catalyses the retro-aldol like cleavage of S1P,
a mechanism has been inferred by analogy to other type 1 PLP
enzymes and from structural studies which have been per-
formed.271 In the resting state, the PLP cofactor is bound to an
active site lysine residue via an imine bond (Fig. 20b). Binding
of the S1P substrate displaces this lysine to form a PLP-SP
external aldimine. An as yet unknown active site base then
deprotonates S1P at the C3 hydroxyl, resulting in cleavage of the
C2/C3 s bond, forming a PEA–PLP quinonoid and releasing 2E-
HEX. Electron rebound from the quinonoid intermediate forms
a PE-PLP external aldimine, before the PE is nally released via
displacement by the active site lysine.
Some debate surrounds the identity of the base required to
initiate the cleavage of S1P with a cysteine residue (Cys317 in
human S1PL) proposed to perform this function.12 Early muta-
tion experiments (C317S) performed before the crystal structure
of S1PL was published, indicated that this residue was required
for lyase activity.12 However, mutation of the equivalent cysteine
in yeast Dpl1p (C344A) had no apparent effect on SPL activity in
an in vivo yeast assay.271 Subsequent analysis of the human S1PL
structure suggests that Cys317 is involved in binding of the PLP
cofactor. As such, the identity of the active site base remains
unknown, and may indeed be a function performed by the PLP
binding lysine (as has been suggested in SPT).5.3 Disease associated mutations in S1PL
Since S1PL plays such an important role in modulating cellular
S1P levels it is not surprising to nd that mutations of the
enzyme result in various diseases. For example in a recent studyNat. Prod. Rep.of steroid-resistant nephrotic syndrome (SRNS) which causes
15% of the cases of chronic kidney disease, a genome analysis of
SRNS-affected families revealed mutations in their S1PL
genes.286 Biochemical studies explored the impact of such
mutations on S1PL activity. Two such mutations (S346I and
R222Q) are loss-of-function changes that lead to reduced
protein levels and enzyme activity, as well as impaired degra-
dation of long-chain sphingoid bases.
Lovric et al. also modelled the mutations of the human S1PL
structure to gain insight into the molecular basis of human
disease. These studies suggest that the R222Qmutation leads to
a loss of two critical hydrogen bonding interactions at the dimer
interface between Arg222 and the backbone Tyr250 and Ser249
residues. This increases the instability of the protein. The
second S346I mutation is predicted to destabilise hydrogen
bonding networks within the protein. Ser346 is buried deep
within the S1PL structure and it is suggested that the sterically
bulky isoleucine residue will cause steric clashes with nearby
residues.
6 Conclusions
The vital role that SLs play in mammalian cell biology has been
recognised for some time. More recently the importance of SL
metabolism in various microbial species has gained increased
attention. This then suggests that SLs are important players in
mediating host/microbial interactions both in the context of
benecial, mutually-symbiotic relationships (e.g. the micro-
biome) but also in a harmful pathogenicity.
This review has discussed the biosynthesis and metabolism
of LCBs highlighting studies of enzymes which have been
investigated with detailed structural and mechanistic methods.
In the most simple microbial systems where the enzymes are
soluble, cytoplasmic and available in highly homogeneous
recombinant forms (e.g. S. paucimobilis SPT), high resolutionThis journal is © The Royal Society of Chemistry 2018























































































View Article Onlinecrystal structures have provided insight into the molecular
mechanism of these enzyme-catalysed conversions. They have
also provided models for the more complicated, membrane-
bound, multi-subunit complexes which have been identied
in eukaryotes. These studies have also allowed us to hypothesise
on the impacts of genetic mutation of SL-enzymes (e.g. HSAN1)
at the molecular level. A key, over-arching theme in SL metab-
olism is that the cell must maintain a balanced pool of sphin-
golipidome components that allows it to generate SLs from the
L-serine and fatty acid pools in times of need, but also degrade
SLs and ceramides since these are potentially toxic if allowed to
accumulate. One interesting area to investigate is the roles that
are played by the so-called deoxy-SLs (derived from L-alanine
and glycine) which represent biomarkers for diseases such as
diabetes.287,288
It would make sense to tightly regulate SL metabolism by
controlling the catalytic activity of key enzymes in the pathway.
These include those enzymes discussed here (SPT, SK, S1PL)
and others that space prohibited us from reviewing (e.g. the
ceramide synthase (CS) and the sphingomyelin synthase (SMS)
families and associated degradation enzymes289–291). The
increasingly complicated nature of the multi-subunit SPT, the
rst enzyme in all eukaryotes that make SLs, has revealed it is
much more complex than initially thought and is associated
with activators and regulators.
The complex nature of the enzymes involved in SL metabo-
lism has not prevented drug companies from targeting this
pathway in the hope of generating new therapeutics.176,177 This
is exemplied by Fingolimod, a clinical success in the treatment
of MS, derived from myriocin by a medicinal chemistry pro-
gramme.292 Natural products have key roles in SL metabolism.
Detailed structural and biochemical studies will aid in the
discovery of new interventions, for which natural products will
undoubtedly provide lead compounds.
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34 G. Schneider, H. Käck and Y. Lindqvist, Structure, 2000, 8,
R1–R6.
35 G. A. Hunter and G. C. Ferreira, Biochim. Biophys. Acta,
Proteins Proteomics, 2011, 1814, 1467–1473.
36 A. J. Edgar and J. M. Polak, Eur. J. Biochem., 2000, 267, 1805–
1812.
37 J. M. Henke and B. L. Bassler, J. Bacteriol., 2004, 186, 6902–
6914.
38 K. Hanada, Biochim. Biophys. Acta, 2003, 1632, 16–30.
39 B. A. Yard, L. G. Carter, K. A. Johnson, I. M. Overton,
M. Dorward, H. Liu, S. A. McMahon, M. Oke, D. Puech,
G. J. Barton, J. H. Naismith and D. J. Campopiano, J. Mol.
Biol., 2007, 370, 870–886.
40 J. Lowther, G. Charmier, M. C. Raman, H. Ikushiro,
H. Hayashi and D. J. Campopiano, FEBS Lett., 2011, 585,
1729–1734.
41 A. E. Beattie, D. J. Clarke, J. M. Wadsworth, J. Lowther,
H.-L. Sin and D. J. Campopiano, Chem. Commun., 2013,
49, 7058–7060.
42 H. Ikushiro, M. M. Islam, H. Tojo and H. Hayashi, J.
Bacteriol., 2007, 189, 5749–5761.
43 H. Ikushiro, S. Fujii, Y. Shiraiwa and H. Hayashi, J. Biol.
Chem., 2008, 283, 7542–7553.
44 H. Ikushiro, H. Hayashi and H. Kagamiyama, J. Biol. Chem.,
2001, 276, 18249–18256.
45 H. Ikushiro, H. Hayashi and H. Kagamiyama, Biochemistry,
2004, 43, 1082–1092.
46 K. Krisnangkura and C. C. Sweeley, J. Biol. Chem., 1976, 251,
1597–1602.
47 O. Ploux and A. Marquet, Eur. J. Biochem., 1996, 236, 301–
308.
48 A. Laghai and P. M. Jordan, Biochem. Soc. Trans., 1977, 5,
299–300.
49 M. M. Abboud, P. M. Jordan and M. Akhtar, J. Chem. Soc.
Chem. Commun., 1974, 643–644.
50 O. Kerbarh, D. J. Campopiano and R. L. Baxter, Chem.
Commun., 2006, 60–62, DOI: 10.1039/B511837A.
51 M. Kato, Y. Muto, K. Tanaka-Bandoh, K. Watanabe and
K. Ueno, Anaerobe, 1995, 1, 135–139.Nat. Prod. Rep.52 K. Kawahara, H. Kuraishi and U. Zahringer, J. Ind.
Microbiol. Biotechnol., 1999, 23, 408–413.
53 M. Lev and A. F. Milford, Arch. Biochem. Biophys., 1981, 212,
424–431.
54 M. C. C. Raman, K. A. Johnson, D. J. Clarke, J. H. Naismith
and D. J. Campopiano, Biopolymers, 2010, 93, 811–822.
55 Y. Watanabe, M. Nakajima, T. Hoshino, K. Jayasimhulu,
E. E. Brooks and E. S. Kaneshiro, Lipids, 2001, 36, 513–519.
56 E. S. Kaneshiro, S. M. Hunt and Y. Watanabe, Biochem.
Biophys. Res. Commun., 2008, 367, 21–25.
57 H. Ikushiro, A. Okamoto and H. Hayashi, in Sphingolipid
Biology, ed. Y. Hirabayashi, Y. Igarashi and A. H. Merrill,
Springer, Japan, Tokyo, 2006, pp. 483–492.
58 H. Ikushiro, M. M. Islam, A. Okamoto, J. Hoseki,
T. Murakawa, S. Fujii, I. Miyahara and H. Hayashi,
J. Biochem., 2009, 146, 549–562.
59 M. C. C. Raman, K. A. Johnson, B. A. Yard, J. Lowther,
L. G. Carter, J. H. Naismith and D. J. Campopiano, J. Biol.
Chem., 2009, 284, 17328–17339.
60 W. R. Griswold and M. D. Toney, J. Am. Chem. Soc., 2011,
133, 14823–14830.
61 Y. Shiraiwa, H. Ikushiro and H. Hayashi, J. Biol. Chem.,
2009, 284, 15487–15495.
62 H. Ikushiro and H. Hayashi, Biochim. Biophys. Acta, Proteins
Proteomics, 2011, 1814, 1474–1480.
63 H. C. Dunathan, Proc. Natl. Acad. Sci. U. S. A., 1966, 55, 712–
716.
64 R. A. Alegado, L. W. Brown, S. Cao, R. K. Dermenjian,
R. Zuzow, S. R. Fairclough, J. Clardy and N. King, eLife,
2012, 1, e00013.
65 H. M. Wexler, Clin. Microbiol. Rev., 2007, 20, 593–621.
66 D. An, C. Na, J. Bielawski, Y. A. Hannun and D. L. Kasper,
Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 4666–4671.
67 C. L. Sears, Clin. Microbiol. Rev., 2009, 22, 349–369.
68 L. C. Wieland Brown, C. Penaranda, P. C. Kashyap,
B. B. Williams, J. Clardy, M. Kronenberg,
J. L. Sonnenburg, L. E. Comstock, J. A. Bluestone and
M. A. Fischbach, PLoS Biol., 2013, 11, e1001610.
69 D. An, S. F. Oh, T. Olszak, J. F. Neves, F. Y. Avci, D. Erturk-
Hasdemir, X. Lu, S. Zeissig, R. S. Blumberg and
D. L. Kasper, Cell, 2014, 156, 123–133.
70 Z. D. Moye, K. Valiuskyte, F. E. Dewhirst, F. C. Nichols and
M. E. Davey, Front Microbiol., 2016, 7, 1919.
71 F. C. Nichols, J. Lipid Res., 1998, 39, 2360–2372.
72 F. C. Nichols, B. Riep, J. Mun, M. D. Morton, M. T. Bojarski,
F. E. Dewhirst and M. B. Smith, J. Lipid Res., 2004, 45, 2317–
2330.
73 J. Mun, A. Onorato, F. C. Nichols, M. D. Morton, A. I. Saleh,
M. Welzel and M. B. Smith, Org. Biomol. Chem., 2007, 5,
3826–3833.
74 S. L. Heaver, E. L. Johnson and R. E. Ley, Curr. Opin.
Microbiol., 2018, 43, 92–99.
75 F. C. Nichols, X. Yao, B. Bajrami, J. Downes, S. M. Finegold,
E. Knee, J. J. Gallagher, W. J. Housley and R. B. Clark, PLoS
One, 2011, 6, e16771.
76 W. H. Wilson, D. C. Schroeder, M. J. Allen, M. T. G. Holden,
J. Parkhill, B. G. Barrell, C. Churcher, N. Hamlin,This journal is © The Royal Society of Chemistry 2018























































































View Article OnlineK. Mungall, H. Norbertczak, M. A. Quail, C. Price,
E. Rabbinowitsch, D. Walker, M. Craigon, D. Roy and
P. Ghazal, Science, 2005, 309, 1090–1092.
77 A. Vardi, B. A. S. Van Mooy, H. F. Fredricks, K. J. Popendorf,
J. E. Ossolinski, L. Haramaty and K. D. Bidle, Science, 2009,
326, 861–865.
78 S. Rosenwasser, C. Ziv, S. G. v. Creveld and A. Vardi, Trends
Microbiol., 2016, 24, 821–832.
79 K. D. Bidle, L. Haramaty, J. Barcelose Ramos and
P. Falkowski, Proc. Natl. Acad. Sci. U. S. A., 2007, 104,
6049–6054.
80 G. Han, K. Gable, L. Yan, M. J. Allen, W. H. Wilson,
P. Moitra, J. M. Harmon and T. M. Dunn, J. Biol. Chem.,
2006, 281, 39935–39942.
81 C. Ziv, S. Malitsky, A. Othman, S. Ben-Dor, Y. Wei, S. Zheng,
A. Aharoni, T. Hornemann and A. Vardi, Proc. Natl. Acad.
Sci. U. S. A., 2016, 113, E1907–E1916.
82 M. M. Nagiec, J. A. Baltisberger, G. B. Wells, R. L. Lester and
R. C. Dickson, Proc. Natl. Acad. Sci. U. S. A., 1994, 91, 7899–
7902.
83 G. B. Wells and R. L. Lester, J. Biol. Chem., 1983, 258, 10200–
10203.
84 W. J. Pinto, G. W. Wells and R. L. Lester, J. Bacteriol., 1992,
174, 2575–2581.
85 W. J. Pinto, B. Srinivasan, S. Shepherd, A. Schmidt,
R. C. Dickson and R. L. Lester, J. Bacteriol., 1992, 174,
2565–2574.
86 R. Buede, C. Rinker-Schaffer, W. J. Pinto, R. L. Lester and
R. C. Dickson, J. Bacteriol., 1991, 173, 4325–4332.
87 C. Zhao, T. Beeler and T. Dunn, J. Biol. Chem., 1994, 269,
21480–21488.
88 J. J. Mukherjee and E. E. Dekker, Biochim. Biophys. Acta,
Protein Struct. Mol. Enzymol., 1990, 1037, 24–29.
89 D. Alexeev, M. Alexeeva, R. L. Baxter, D. J. Campopiano,
S. P. Webster and L. Sawyer, J. Mol. Biol., 1998, 284, 401–
419.
90 K. Gable, G. Han, E. Monaghan, D. Bacikova, M. Natarajan,
R. Williams and T. M. Dunn, J. Biol. Chem., 2002, 277,
10194–10200.
91 K. Gable, H. Slife, D. Bacikova, E. Monaghan and
T. M. Dunn, J. Biol. Chem., 2000, 275, 7597–7603.
92 G. Han, K. Gable, L. Yan, M. Natarajan, J. Krishnamurthy,
S. D. Gupta, A. Borovitskaya, J. M. Harmon and
T. M. Dunn, J. Biol. Chem., 2004, 279, 53707–53716.
93 B. Weiss andW. Stoffel, Eur. J. Biochem., 1997, 249, 239–247.
94 M. M. Nagiec, R. L. Lester and R. C. Dickson, Gene, 1996,
177, 237–241.
95 K. Hanada, T. Hara, M. Nishijima, O. Kuge, R. C. Dickson
and M. M. Nagiec, J. Biol. Chem., 1997, 272, 32108–32114.
96 K. Hanada, T. Hara and M. Nishijima, J. Biol. Chem., 2000,
275, 8409–8415.
97 A. A. Momin, H. Park, J. C. Allegood, M. Leipelt, S. L. Kelly,
A. H. Merrill and K. Hanada, Lipids, 2009, 44, 725–732.
98 S. Yasuda, M. Nishijima and K. Hanada, J. Biol. Chem., 2003,
278, 4176–4183.
99 T. Hornemann, S. Richard, M. F. Rütti, Y. Wei and A. von
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P. Seeman, P. De Jonghe, P. Van Dijck, A. Jordanova,
T. Hornemann and V. Timmerman, Am. J. Hum. Genet.,
2010, 87, 513–522.
127 S. Suriyanarayanan, M. Auranen, J. Toppila, A. Paetau,
M. Shcherbii, E. Palin, Y. Wei, T. Lohioja, B. Schlotter-
Weigel, U. Schon, A. Abicht, B. Rautenstrauss,
H. Tyynismaa, M. C. Walter, T. Hornemann and
E. Ylikallio, NeuroMol. Med., 2016, 18, 81–90.
128 K. Garofalo, A. Penno, B. P. Schmidt, H. J. Lee, M. P. Frosch,
A. von Eckardstein, R. H. Brown, T. Hornemann and
F. S. Eichler, J. Clin. Invest., 2011, 121, 4735–4745.
129 M. Auranen, J. Toppila, S. Suriyanarayanan, M. A. Lone,
A. Paetau, H. Tyynismaa, T. Hornemann and E. Ylikallio,
Cold Spring Harbor Mol. Case Stud., 2017, a002212, DOI:
10.1101/mcs.a002212.
130 T. M. Dunn, D. V. Lynch, L. V. Michaelson and J. A. Napier,
Ann. Bot., 2004, 93, 483–497.
131 D. Worrall, Y.-K. Liang, S. Alvarez, G. H. Holroyd, S. Spiegel,
M. Panagopulos, J. E. Gray and A. M. Hetherington, Plant J.,
2008, 56, 64–72.
132 S. Coursol, L.-M. Fan, H. L. Stunff, S. Spiegel, S. Gilroy and
S. M. Assmann, Nature, 2003, 423, 651–654.
133 C. Dutilleul, G. Benhassaine-Kesri, C. Demandre, N. Rézé,
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